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The literature in relation to immunological
enhancement is reviewed. The development and technique
of heart transplantation in the rat is described and the
value of this experimental model is assessed.
Studies are presented showing that intravenous pre-
treatment of cardiac allograft recipients with donor
strain blood induced marked prolongation of graft
survival. Skin allograft survival was slightly
prolonged by similar means. Using blood from rats of a
strain which differed at the major histocompatibility
locus from either the graft donor or recipient the effect
was shown to be immunologically specific. Pre-treatment
with thoracic duct lymphocytes and with spleen cells of
donor strain induced prolongation of cardiac allograft
survival similar to that following injection of whole
blood. Administration of donor strain erythrocytes and
plasma did not affect graft survival.
Using donor strain spleen cells the optimum
7
conditions of pre-treatment were assessed. 10 cells
injected intravenously two weeks prior to transplantation
produced the maximum increase in graft survival. The
same number of cells given as late as during the
transplant operation, though less effective, still
resulted in a highly significant prolongation of graft
survival. Cells given on the day after transplantation
were without effect.
The prolonged survival of cardiac allografts in pre-
treated rats was not reduced by injection of further donor
strain blood or of sensitised recipient strain spleen
cells given two to three weeks after transplantation.
Antibody studies were performed on rats pre-treated
with donor strain blood, on rats receiving cardiac
allografts, and on pre-treated rats which subsequently
received cardiac allografts. Injection of donor strain
blood induced high titres of cytotoxic antibody one week
after injection. This was shown to be mostly of 19S
class. At two weeks this had subsided and was succeeded
by a more prolonged response which at two weeks was shown
to be mainly of 7S class. The titres of this second
response were raised following transplantation of a
cardiac allograft two weeks after blood pre-treatment.
Passive transfer of serum from rats injected with
donor strain blood did not induce prolongation of graft
survival in otherwise untreated recipients. Similar
-vi-
serum perfused through the coronary circulation of
isolated hearts immediately before transplantation also
did not affect graft survival time.
Using hybrid animals the reproducibility of the
graft-versus-host assay of Ford, Burr and Simonsen (1970)
was tested. This assay was used to evaluate the immuno-
competence of thoracic duct lymphocytes of rats pre-
treated with donor strain blood. Such cells showed
normal graft-versus-host reactivity. As a further test
of immunocompetence pre-treated rats bearing long
surviving cardiac allografts received skin grafts of
donor strain. Such grafts were rejected in the time
characteristic of control skin grafts. These results
show that the pre-treatment schedule used in these
studies did not induce a state of immunological tolerance
in the sense which was implied by Billingham, Brent and
Medawar (1953).
The final experiment was designed to assess possible
alteration of antigenicity of long surviving cardiac
allografts borne by pre-treated rats. The hearts were
retransplanted into untreated rats of donor and recipient
strain. In the former indefinite graft survival
occurred. In rats of recipient strain the survival of
-vii-
a proportion of retransplanted hearts was prolonged«
The possible role of immunological enhancement in
the experiments is discussed„
It is concluded that the phenomenon may be of
potential value in clinical transplantation, but owing
to species differences experimental results obtained with
rats are not necessarily directly applicable to man.
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STATISTICAL ANALYSIS AJSFD PRESENTATION OF RESULTS
In the presentation of the experimental results in
this thesis the following mathematical and statistical
techniques have been applied (Snedicor, 1956).
Arithmetical means are shown together with standard
errors „ Geometric means are followed by numbers in
parenthesis which show the effect of adding or
subtracting 1 standard error of the log mean.
Comparison between means have been made using Studentrs t
Test. The probabilities cited with this test are
designated N,S, when not significant. Otherwise they
are expressed as 0„05 to 0.001. Only those probabilit¬




Organ transplantation provides a unique approach to
human illness in which failure of, or damage to, a vital
organ may jeopardize the life of the individual. The
potential of transplant surgery has been recognised
increasingly in recent years, and this has led to
resolution of many of the purely technical problems.
The introduction of extracorporeal circulation with
cardiac bypass brought within the bounds of possibility
replacement of the heart itself and surgical techniques
have now proved this to be feasible. Griepp, Stinson,
Dong, Clark and Shumway (1971) reported a series of 26
such transplants, and more than a quarter of the patients
were alive at the end of one year. Kidney transplants
have now become routine and the 8th Report of the Human
Kidney Transplant Registry (1971) records data from a
total of 3»645 transplants. Experimentation with
transplants of other organs is proceeding. However
although technical problems associated with transplantat¬
ion are being steadily resolved, the solution to rejection
of allografts remains.
The phenomenon of rejection was reviewed by Loeb in
-2-
1930. The characteristic features of round cell
infiltration, vascular stasis, oedema and necrosis of
grafts are now familiar to all concerned with transplant
surgery. The success of grafts exchanged between
identical twins underlines the immunological basis of
rejection of grafts between unrelated individuals.
The search for methods of preventing rejection of
allografts has led to a diversity of approaches. One
is aimed at circumventing the problem by matching the
tissue types of donor and recipient and has been
reviewed by Joysey (1971). This concept promoted the
formation of the organisation 'Eurotransplant' which
types and distributes organs to centres having the most
closely compatible recipients available. Some success
has been claimed for the scheme with regard to improved
survival of renal transplants (van Rood, van Leeuwen,
Pearce and van der Does, 1969). The complexity of the
Human Leucocyte Antigen (HL-A) system however makes
perfect matching extremely difficult to obtain in
practice. Kissmeyer-Nielsen, Svejgaard and Hauge (l969)
calculated that 1008 different HL-A phenotypes are
possible, and that a random chance of finding two
unrelated individuals with identical tissue types is
-3-
approximately 1 in 1000. A very large recipient pool is
necessary therefore to give a reasonable chance of
perfect matching between recipient and donor. The
difficulty of achieving this limits the value of the
scheme.
An alternative approach to the problem of rejection
is the use of immunosuppressives. These can be
categorised broadly as those with a specific and those
with a non-specific mode of action. Specific immuno¬
suppressives do not interfere with antibody response to
infection and do not produce overall depression of cell
mediated immunity. Non-specific immunosuppressives on
the other hand produce overall depression of both humoral
and cell mediated immunity. If immunosuppression is
profound overwhelming infection is liable to occur (Evans,
1969)j and interference with cell mediated immunity
increases the likelihood of neoplasia arising spontaneous¬
ly in the recipient. This occurrence has been reported
on numerous occasions (Doak, Montgomerie, North and
Smith, 1968; 'Woodruff, 1968), and has been reviewed by
Penn (l97l) and by Smellie (1971). Penn (1971) found
a 6.7 per cent incidence of malignancy in immunosuppressed
renal allograft recipients. This compared with an
-k-
incidence of malignancy in the general population of
similar age of 58 per 100,000 „ The frequent occurrence
of reticulum cell sarcomas in renal allograft recipients
was also noted. In a review by Schwartz and
Andre-Schwartz (1968) evidence is presented suggesting
that immunosuppress!on may encourage oncogenic viruses
to induce lymphoproliferative malignancy.
In spite of these disadvantages non-specific
immunosuppression has an established place clinically in
the management of transplant recipients. The purine
analogue azathioprine (Imuran) was shown by Calne and
Murray in I96I to produce prolongation of survival of
canine renal allografts. It has been used clinically
since 1962 and remains the most widely used immuno¬
suppressive drug.
X-irradiation also has a non-specific immuno¬
suppressive action. Murray, Merrill, Dammin, Dealy,
Walter, Brooke and Wilson (i960) reported the results
of a clinical trial of immunosuppression by total body
irradiation and noted a high incidence of bone marrow
depression and overwhelming infection. Immunosuppress¬
ion by this means is no longer advocated. Local
irradiation to the graft was evaluated by Hume, Magee,
-5-
Kauffman, Rittenbury and Prout (1963) and has been used
with success in some centres (Starzl, 1964; Calne, 1967).
Corticosteroids have been employed for a number of
years as an adjunct to other immunosuppressive drug
therapy, but they have not proven their value as primary
immunosuppressive agents.
The capacity of heterologous antilymphocyte serum
(ALS) to delay rejection of allografts was first
demonstrated by Woodruff and Anderson in 1964, and
represents an important advance in immunosuppression.
Although ALS is essentially non-specific in its mode of
action it has the advantage of acting primarily on cells
responsible for mounting cellular immune reactions.
The complications attended by the use of non¬
specific immunosuppressive agents has focused attention
on the capacity of specific phenomena including
immunological enhancement and tolerance to induce
suppression of allograft rejection. By such means it
might be possible to prevent rejection without
interfering with the overall immunocompetence of the
graft recipient.
The object of experiments presented in this thesis
is the demonstration and investigation of prolongation of
-6-
cardiac allograft survival in rats which follows pre-
treatment of recipients with donor strain cells. An
attempt has been made to establish the mechanism of the
effect.
The presence of a number of inbred strains make the
rat an ideal experimental animal when strict standard¬
isation of experiments is required, and microvascular
techniques have made heterotopic heart transplantation
possible in this species. A highly satisfactory and
reproducible experimental model has resulted.
Calne (1971) has drawn attention to the spectrum of
susceptibility to rejection which exists between skin,
heart, kidney and liver allografts within a species, and
noted that liver transplants are rejected least
aggressively. This serves as a reminder that
experimental results obtained using allografts of one
tissue may not be valid for another. As well as this
species differences are of obvious importance, and it
would be unwise to apply experimental results using rats
equally to man or to other species since quantitative
or qualitative differences of immunological response may
exist between them. It is of interest that unlike the
rat human recipients of renal allografts who have
-7-
detectable cytotoxic antibody before transplantation
reject their grafts in a hyperacute fashion (Kissmeyer-
Nielsen, Olsen, Petersen and Fjeldborg, 1966; Williams,
Hume, Hudson, Morris, Katio and Milgrom, 1967; Terasaki,
Thasher and Hauber, 1968; Russell, 197l) •
In spite of this warning note it is possible that
specific immunosuppression in some degree may be
applicable to clinical transplantation. It is hoped
that the experiments in this thesis at least in a small
way will help to promote further interest and research
into a phenomenon of such possible potential importance.
CHAPTER X
A review of the literature
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THE DEVELOPMENT OF THE CONCEPT OF IMMUNOLOGICAL
ENHANCEMENT
The phenomenon of enhancement was first noted by
Flexner and Jobling (1907) who found that growth of a rat
sarcoma was favoured if the host was pre-treated with an
emulsion of the tumour cells which had been heated at
56°C for half an hour„ The first systematic study was
by Casey (1932, 1934a, 1934b, 1941) and Casey, Meyers and
Drysdale (1948). They found that Brown-Pearce carcinoma
of rabbits grew and metastasised more rapidly and widely
in recipients pre-treated with killed homologous tumour
tissue. They also demonstrated the specificity of the
effect using transplantable tumours in mice.
This was followed by reports which showed that the
effect on mouse tumours could be produced equally well
using donor strain spleen, kidney, and liver cells as
distinct from tumour tissue to pre-treat the tumour host
(Kaliss and Snell, 1951; Snell, 1952; Day, Kaliss,
Aronson, Bryant, Friendly, Gabrielson and Smith, 1954).
These findings indicated that the effect was not induced
by a growth promoting agent contained in the tumour
extract, and also that tumour-specific antigens are not
relevant to enhancing phenomena.
-9-
Using rats and mice Kaliss and Molomut (l952)>
Kaliss, Molomut, Harriss and Gault (1953) and Kaliss
(1955) demonstrated that enhanced tumour growth could be
passively transferred by injecting serum from animals of
the same strain which had been subjected to enhancing
treatment. The globulin fraction of serum was shown by
Kaliss and Kandutsch (1956) to possess this potential.
In recent years numerous studies of enhancement
have been carried out using normal tissue allografts
instead of tumours and have been reviewed by Batchelor
(1963), Kaliss (1969) and Billingham and Silvers (l97l)°
Billingham and Sparrow (1955) prolonged survival of
rabbit skin grafts by prior treatment of the recipient
with dissociated epidermal cells given intravenously.
Since that time numerous workers have demonstrated
enhancement of skin allografts (Shapiro, Martinez, Smith
and Good, I96I; Guttman and Aust, I96I; Nelson, 1962;
Moller, 1964b).
Following the introduction of microvascular surgical
techniques in i960 it became feasible to transplant
organs in small laboratory animals by vascular
anastomosis, and within a few years Stuart, Saitoh,
Fitch and Spargo (1968) reported prolongation of survival
-10-
of rat renal allografts using pre-treatment schedules of
antiserum alone, donor strain spleen cells alone, and a
combination of these agents in three groups of recipients -
The combined treatment was found to induce marked
prolongation or indefinite survival of the grafts„
Since this important study others have demonstrated
enhancement of organ allografts. Marquet, Heystek and
Tinbergen (1971) produced prolonged survival of rat
cardiac and renal allografts by pre-treatment of
recipients with donor strain blood. Jenkins and
Woodruff (1971) using cardiac allografts confirmed this
finding with a different strain combination and
demonstrated that a similar effect occurred after
injection of donor strain thoracic duct lymphocytes.
Lucas, Markley and Travis (1970) and Ockner, Guttman and
Lindquist (1970a) also reported prolongation of survival
of rat renal allografts following pre-treatment of
recipients with donor strain spleen and bone marrow cells,
and Halasz, Orloff and Hirose (1964) demonstrated delayed
rejection of dog renal allografts after pre-treatment of
recipients with donor blood.
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POSSIBLE MECHANISMS OF IMMUNOLOGICAL ENHANCEMENT
Since the immunological nature of enhancement was
demonstrated by Kaliss and Snell (l95l) numerous
theories of the mechanism of the phenomenon have been
advanced and have been reviewed by Kaliss (1962),
Batchelor (1963), Hutchin (1968), Kaliss (l969), Amos,
Cohen and Klein (1970), Snell (1970), Russell (l97l)>
and Voisin (1971). Following the separation of the
immune response into cellular and humoral components,
Billingham, Brent and Medawar (1956) suggested that
humoral antibodies might in some way block the
destructive effect of a cell mediated response on an
allograft. The "blocking theory" of enhancement arose
from this concept, and Billingham and his associates
suggested that afferent, central, or efferent block of
the cellular immune response might occult. Afferent
blockage implies a block between the original antigen
depot and the immune centres. Central blockage is a
block "which affects the actual machinery of antibody
formation or of some equivalent immunological process".
Efferent blockage is a block "which in some manner
prevents the effectors of the immune reaction from
-12-
exercising their action".
Snell, Winn, Stimpfling and Parker (i960) employed
the Winn Assay of cell mediated immunity (Winn, i960)
to demonstrate that passively transferred antiserum
reduced the cellular immune response to the antigen
against which the antiserum was raised. It was deduced
that the blockage was therefore afferent or central.
This work was extended by Takasugi and Hildemann (1968)
who showed that passively transferred antibody reduced
the lymphocytosis induced by a graft, and also reduced
the immunity shown by circulating lymphocytes. Snell's
deduction that the block was either afferent or central
was therefore confirmed.
In order to differentiate between an afferent or a
central block Takasugi and Hildemann (1968) removed
allografts six days after transplantation. This did not
prevent the lymphocytosis from developing until antibody
was added. It was deduced that the block was probably
central. However there is also good evidence that a
block of the efferent path may occur too. Moller (1963,
1964a) injected mice in the flanks with allogeneic tumour
cells. On one side the cells were coated with allo-
antibody. Subsequent growth occurred on the treated
-13-
side, but not on the untreated side„ Central and
afferent blocks are clearly excluded in this system,,
Most workers now agree that while there is little
evidence that enhancement is produced by an afferent
block, both central and efferent blocks of the immune
response may occur, possibly depending upon the system
used.
An alternative approach is suggested by Guttman,
Lindquist and Ockner (l9^9) who have demonstrated the
importance of donor passenger leucocytes within allo¬
grafts, They suggest that such cells act as the most
powerful immunogens within a graft, and that the action
of enhancing antibody may be to eliminate these cells.
The fundamental nature of enhancement has been
suggested by Hellstrom and Hellstrom (1970) and Hellstrom,
Hellstrom and Allison (l97l) in experiments which have
linked enhancement to neonatally induced tolerance.
They showed that lymph node cells from CBA strain mice
made tolerant to A strain as neonates were cytotoxic to
A strain cultivated fibroblasts in the presence of
control serum. The addition of serum from tolerant CBA
mice nullified this effect which was also shown to be
specific. The inference drawn was that the tolerance
-14-
of the CBA mice was due solely to serum factors. The
borderline between tolerance and enhancement therefore
seems to be indistinct.
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THE DEVELOPMENT OF HETEROTOPIC HEART TRANSPLANTATION
IN THE RAT
Anastomosis of small vessels has presented serious
technical problems for many years. This is reflected
by the numerous methods of anastomosis which have been
advocated, some of which involve vessel suturing and some
the use of splints, rings, staples and tissue adhesives
(Mozes, Man, Agmon and Adar, 1963; Rohman, Goetz and
Dee, I960; Androsov, 1956; Hafner, Fogarty and Cranley,
1963). In general non-suture methods have proved
unsatisfactory for small vessel work and refinements of
technique and instruments have shown that the best
results are obtained by suturing.
The obvious value to immunological research of organ
transplantation in small laboratory animals has
stimulated the testing of numerous different operative
methods.
Heart transplantation by implantation of the graft
was used by Judd and Trentin (1969) in mice. This
involves implantation of foetal hearts into the
subcutaneous tissue of the pinna of the ear of adult
recipients. A similar technique was evaluated by the
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author (unpublished data) using rats, The grafts
pulsate visibly and transmit good E,C,G, recordings
(Plate 1). The advantage of the method lies in its
simplicity, though it is not generally used since the
mode of vascularisation of the grafts is very different
from that in clinical heart transplants.
Transplantation of the rat heart into the neck was
described by Heron (l97l) • "Vascular anastomosis was
achieved using extravascular Teflon prostheses making
it unnecessary to employ microvascular suturing tech¬
niques. A 10 to 15 per cent incidence of thrombosis
was noted.
Sophisticated microvascular techniques were first
employed for transplantation of the rat heart by Abbott,
Lindsey and Creech (1964). Transplantation was
performed by anastomosis of the donor thoracic aorta to
recipient abdominal aorta, and donor pulmonary artery to
recipient inferior vena cava, both in an end-to-end
fashion. Interruption of blood supply to the recipient1 s
caudal region led to a high incidence of post-operative
paraplegia. Modification to end-to-side anastomosis
avoiding transection of the recipientTs great vessels was
shown by Bui-Mong-Hung and Vigano (1966), and by Ono and
-16a-
ISOGENEIC17 DAY FOETAL RAT HEART IN EAR OF
ADULT RECIPIENT AT 6DAYS (HOODED) lOOmm/sec.
Plate 1: ECG recording of foetal rat heart implanted
in ear of adult recipient (isogeneic).
Upper and lower limb leads placed on cheeks
and neck of recipient. Chest lead
transfixed the ear containing the transplant.
Arrows mark complexes produced by the
transplant.
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Lindsey (1969) to produce markedly improved results.
This technique is now used in several centres and has
proved satisfactory (Jenkins and Woodruff, 1971;
Marquet, Heystek and Tinbergen, 1971). It was shown
by the author (unpublished data) to be technically
feasible in the mouse also, though as the diameter of
the aorta is about 0.25 mm* a special degree of surgical
precision is necessary (Plate 2).
Transplantation of the rat heart by this method
has been used throughout the present study.
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MOUSE. HETEROTOPIC CARDIAC ALLOGRAFT
(AKR-C3H) 25 mm/sec
Plate 2: ECG recording of mouse heterotopic cardiac
allograft established by vascular
anastomosis into abdomen of recipient.
Chest lead was placed over the transplant.






a) A2/1 strain (Plate 3)
This strain was produced from a substrain of Wistar
rats known as Ag by Michie and Anderson (1966) at the
University of Edinburgh. In spite of a record of 72
generations of brother-sister matings about 50% of skin
grafts exchanged between A2 rats were rejected. This
was found to be due to a powerful genetic stabilising
effect known as heterosis which resulted in almost every
surviving rat being heterozygous, and further studies
showed that the selective elimination of the homozygous
state occurred at fertilisation.
A new breeding policy resulted in the identification
of a few rats which accepted skin grafts from both
parents. These were then brother-sister mated and free
acceptance of grafts between the progeny showed that an
isogeneic substrain had been produced and which has been
known subsequently as A2/1.
Histocompatibility typing of A2/1 rats has been
performed by Palm (1970) who has shown that they carry
the AgB£ histocompatibility antigen. Anderson, James
and Woodruff (1967) have shown that this strain rejects
Plate 3 '• The albino A2/1 rat.
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split-thickness skin grafts from Hooded rats in 8„6 days
In experiments reported in this thesis A2/l strain
male animals (180-250 G) have acted as donors of cardiac
and skin allografts„
b) Hooded strain (Plate 4)
This strain has been maintained in this laboratory
for over 13 years by brother-sister matings. The rats
are isogeneic and rejection of skin grafts within the
strain does not occur„ The strain is known to carry
the AgBe; histocompatibility antigen, and Anderson, James
and Woodruff (1967) have shown that they reject A2/1
split-thickness skin grafts in 8.1 days.
Male Hooded rats (180-250 G) have acted as
recipients of heart and skin allografts in these
experiments. They have also been used in some
experiments to raise alloantiserum.
c ) F^ hybrid rat s
Fj hybrid rats were bred by mating a Hooded male
and A2/1 female for one generation in the Department of
Surgery, University of Edinburgh.
Plate 4: The Hooded rat„
•20-
d) Sprague-Dawley rats
In one experiment male rats of this strain (AgBg)
have been employed to provide third party blood.
e) Lewis strain
Male rats of this strain also have been used to
provide third party blood, and were generously provided
by Professor K. Porter, St. Mary's Hospital Medical
School, London. The histocompatibility status of this
strain is AgB-^.
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2. HETEROTOPIC HEART TRANSPLANTATION
a) Anaesthesia
Donor animals
Anaesthesia was induced in an ether chamber for
all donor animals. Following shaving of the abdomen and
chest the animals were pinned to an operating board and
anaesthesia was maintained by means of a nose-cone
containing ether. This type of anaesthetic was also
used for other procedures such as thoracic duct
cannulation and skin grafting.
Recipient animals
0.1-0.15 ml. of veterinary nembutal, depending
on the weight of the rat, given intraperitoneally was
used for all heart recipients. This anaesthetic agent
was found to be reliable, and with experience a dose
could be estimated which would allow the animal to wake
at the time that the operation ended. On occasion
supplementary ether was required. It was found that
the use of nembutal as the main anaesthetic agent
instead of ether resulted in a lowering of respiratory
problems during and after transplantation.
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b) Instruments and equipment used in transplantation
1o Operating microscope
In order to obtain technically perfect vascular
anastomoses a Zeiss binocular operating microscope was
used for all cardiac transplants(Plate 5). The
instrument is a diploscope which enables an assistant
to help when necessary. However except in heart
re-transplant operations assistance was not used. The
operating microscope has a wide range of magnification
available, from x6 to x.kO, but xlO magnification was
found to be optimum„ The illumination does not produce
appreciable heating of the operative field and does not
therefore cause drying of the tissues.
2. Operating instruments (Plate 6)
No instruments specially made for microvascular
work were used. Ophthalmic instruments were found to be
satisfactory, and these included iris scissors for
opening the recipient vessels, Castroviejo pattern needle-
holding forceps, and very fine tissue forceps.
Castroviejo corneal scissors were found ideal for
transecting the donor aorta and pulmonary artery at the
level of the transverse sinus.
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HERSUTURES Ejiltu Needled Suture |
QPQP
Plate 6: Instruments and suture material used in
heterotopic heart transplantation„
1. Artery forceps
2. 3 fine dissecting forceps (plain,
toothed, curved)
3. Retractors and vascular clamps
k. Suture material
5. Needle-holder-scissors
6. Castroviejo needle-holder and
corneal scissors
7. Two pairs fine iris scissors
8 „ Mayo scissors
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Small bulldog vascular clamps served to occlude
the recipient vessels during transplantation. Small
pellets of Kleenex tissues were found to absorb
extravasated blood more satisfactorily than cotton wool
pellets o
3. Suture materials
8/0 Ethilon (Ethicon) monofilament nylon sutures
mounted on a curved 8 mm. round bodied needle were used
for all anastomoses (Plate 7). This material was found
to be more suitable than silk which tended to saw through
fine vessels. Its slight springiness made picking up
with needle-holding forceps during knot tying easy as
unlike silk it does not adhere to surrounding tissues.
With this fine grade of nylon no tendency for knots to
slip was noted.
5/0 braided silk was used for tying small
communicating vessels and for ligating donor cavae and
pulmonary veins.
-23a-
Plate 7: Monofilament nylon suture mounted on a




The technique employed in these studies was similar
to that described by Bui-Mong-Hung and Yigano (l966) and
Ono and Lindsey (l969)» in which end-to-side anastomoses
are made between donor ascending aorta and recipient
abdominal aorta, and between donor pulmonary artery and
recipient inferior vena cava. The donor cavae and
pulmonary veins are ligated allowing a simple coronary
perfusion of the graft. Such grafts are fully
pulsatile on restoration of circulation.
(i) Donor animal
Heparinisation. The mesentery is exposed
through a midline abdominal incision and 300 units of
heparin are injected into a mesenteric vein.
Exposure. The rib cage is divided along its
lateral aspects and the anterior fibres of the diaphragm
are detached from the anterior chest wall. The
resulting flap of chest wall is hinged in a cephalad
direction to expose the heart and is retained by means
of a needle which transfixes the xiphisternum and
passes into the operating board (Plate 8).
Removal of the heart. The pericardium is
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Plate 8; Removal of heart from donor rat.
The anterior chest wall is hinged in a
cephalad direction. A scissor blade is
passed through the transverse sinus and
the aorta and pulmonary artery are
transected together.
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opened and the inferior vena cava is ligated with 5/0
silk and is divided„ A blade of a pair of corneal
scissors is passed through the transverse sinus of the
heart, and the ascending aorta and pulmonary artery are
transected together. A silk ligature is passed round
the pulmonary veins and inferior cavae, and these vessels
are divided en masse distal to the ligature.
Perfusion and immersion of the isolated heart.
Perfusion of the aortic stump with 2 ml. of 0.9% saline
at 4°C is carried out through a Pasteur pipette. This
causes myocardial contractions to cease. The heart is
placed in cold saline for an average of 8 minutes before
transplantation.
(ii) Recipient animal
Position and incision. The animal is placed
supine on the operating board and the hind limbs are
secured to the board with rubber leg bands. The fore
limbs are left free to avoid impeding respiratory
movement. A midline xipho-pubic incision is used and
retractors are inserted to give exposure.
Exposure of aorta and vena cava. The gut is
packed in damp swabs and the mesocolon is divided giving
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access to the abdominal aorta and vena cava. Peritoneum
and fat are wiped from these vessels with pellets of
rolled Kleenex tissues, and the splanchnic nerves lying
on the aorta are stripped from the vessel and divided
(Plate 9). A point midway between the origin of the
renal vessels and the aortic bifurcation is selected for
anastomosis of the donor heart, and aortic branches and
caval tributaries are ligated in that segment. Two
small vascular clamps are used to isolate the segment.
Anastomosis. The aorta and vena cava are
opened through small vertical incisions. The donor and
recipient aortae are approximated with two stay sutures,
and the anastomosis is completed with a continuous
suture of 8/0 Ethilon (Plates 10, 11, 12). On preparing
to insert the last stitch of both anastomoses it is
necessary to leave the previous stitch loose so that the
vascular lumen can be identified otherwise the opposite
wall of the vessel may be picked up with the needle with
obliteration of the vascular lumen. In each case the
vessel lumen is filled with saline prior to closure.
If this step is omitted air embolism of the donor
myocardium destroys a proportion of grafts, and fatal
air embolism has been noted from the venous anastomosis.
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Plate 9: Exposure of the recipient1s inferior vena
cava and aorta,, The colon is retracted
to give exposure„ The lower pole of the
left kidney is visible.
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Plate 10: End to side aortic anastomosis.
Completion of the first side between
upper and lower stay sutures,,
-26c —
End to side aortic anastomosis prior to
suturing of the second side. The heart
is reflected to the left and the lumen of
recipient and donor aortae is exposed.
-26d-
Plate 12 : Completion of aortic anastomosis.
The pulmonary artery is prepared for
anastomosis to the recipient vena cava.
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The left side of the venous anastomosis is
fashioned from within the lumen of the vessels since
the aortic anastomosis prevents normal access. A
similar continuous suture is again employed (plates 13,
14, 15).
Re-establishment of graft circulation (Plates 16,
17, 18). The distal clamp is removed first, and light
pressure with pledgets controls oozing of blood.
Coordinated ventricular contractions return spontaneously
a few moments after removal of the clamps, but in some
instances it is preceeded by a brief period of
ventricular fibrillation (plate 19). The average
period of anoxia of grafts is 25 minutes.
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Plate 13: Anastomosis of pulmonary artery to
inferior vena cava. Completion of the
first side which is performed from within
the vascular lumen.
-27b-
Plate 14: Anastomosis of pulmonary artery to
inferior vena cava. Second side nearing
completion. A probe has been passed
between the aortic and venous anastomoses.
-27c-
Plate 15: Both anastomoses complete„
-27d-
Plate 16: Aortic anastomosis following removal
of vascular clamps.
Plate 17: Transplant in relation to viscera.
Colon to left, stomach, above and to right,
kidney to right, seminal vesicles below.
r
-2-7e-
Plate 18: The transplanted heart is allowed to lie
free among the coils of small bowel.
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HETEROTOPIC RAT CARDIAC ALLOGRAFT. SHOWING DEFIBRILLATION
25 SECONDS AFTER COMPLETION OF TRANSPLANTATION .
Plate 19: ECG recording of heterotopic heart
transplant shortly after removal of
the vascular clamps. Spontaneous
defibrillation is shown occurring
25 seconds after circulatory return.
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3. ASSESSMENT OP GRAFT ACTIVITY
Grafts were considered to have been rejected when
no pulsatile activity was present, and an E,C„G.
recording was flat. Rejection of hearts was
subsequently confirmed histologically.
a) Palpation. This was carried out daily, other than
with hearts active for in excess of k weeks. These
were examined thrice weekly. On occasion the recipient
had to be anaesthetised especially when the amplitude of
pulsation had diminished as before rejection. It was
found that the force of the blood entering an inactive
graft could give an erroneous impression of contract-
ibility, and that this factor could be eliminated by
pressure occlusion of the recipient's aorta proximal
to the graft during palpation.
b) E ,C .G. A direct writing ink jet electrocardiogram
(Mingograf, Sierex) was used throughout the study
(Plate 20). Animals subjected to this examination
were anaesthetised briefly with ether. As shown by
Abbott, DeWitt and Creech (1965) and Bui-Mong-Hung and
-28a-
Plate 20; The Mingograf (Sierex) electrocardiogram
in use.
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Vigano (1966) positioning of the upper limb leads in the
subcostal region or near the iliac crests, and the
exploring electrode over the transplant served to
suppress or eliminate interference from the animal1s own
heart (Plate 21). By adjusting the position of the
exploring electrode activity from the animal's own heart
and that from one or more transplants could be recorded
on one tracing (plates 22 and 23). A newly transplanted
heart adopts a regular rhythm independent of the animal's
own heart, but often approximating to it in rate.
Preceeding this there is frequently a variable period of
bradycardia associated with defective intraventricular
conduction. This may be caused by the trauma and anoxia
of transplantation. Abbott, Creech and DeWitt (1965)
showed that isografts produce a relatively normal E.C.G,
tracing indefinitely. During rejection of allografts
the E.C„G. tracing shows progressive loss of amplitude
of QRS complexes, defective intraventricular conduction,
marked bradycardia and finally when rejection is
complete, a flat tracing.
c) Histology. At the time of rejection control
allografts showed a severe allograft reaction with
-29a-
Plate 21: Positioning of" ECG leads for recording of
a cardiac transplant. The upper limb
leads are placed in the subcostal area,
and the exploring electrode over the
transplant„
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L22 ABDOMINAL CARDIAC ALLOGRAFT (A2/1 - HOODED)
10 DAYS POST TRANSPLANTATION. 100 mm / sec.
Plate 22; ECG recording (lOO mms/sec) showing
complexes produced by a single heterotopic
cardiac allograft in the lower tracing
(marked with „).
2 ABDOMINAL CARDIAC ALLOGRAFTS ( A2/ 1 - HOODED ) "
GRAFT A - 196 DAYS POST TRANSPLANTATION.
GRAFT B '/2 HOUR POST TRANSPLANTATION 100mm/sec.
Plate 23: ECG recording (lOO mms/sec) showing
complexes produced by 2 heterotopic
cardiac allografts (a and b) in the
lower tracing.
Graft A - 196 days post transplantation
Graft B - hour post transplantation
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destruct ion. of much, of the muscle component as observed
by Abbott, Creech and DeWitt (1964), Abbott, DeWitt and
Creech (1965) and van Bekkum, Heystek and Marquet (l969)
(Plate 24). Such hearts had marked oedema of the
myocardium associated with a diffuse cellular infiltrate.
Scattered areas of haemorrhage also occurred. The
cellular infiltrate consisted of lymphocytes and plasma
cells but foci of polymorphonuclear cells were also
present around areas of muscle necrosis„ There was
little intimal proliferation of the coronary vessels of
hearts which were rejected acutely.
In contrast those hearts which were subjected to
chronic rejection showed myocardial destruction with
extensive fibrous replacement„ There was marked
coronary arteritis with intimal proliferation and
frequently obliteration of the vascular lumen (Plate 25) »
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Plate 2k: Myocardium of cardiac allograft 1k days
after transplantation showing marked
destruction of the muscle component with
cellular infiltration„
Plate 25: Myocardium and coronary vessel of cardiac
allograft 162 days after transplantation
into recipient pre-treated with donor
strain blood„ There is obliteration of
the muscle component and marked coronary
arteritis„
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k. TECHNIQUE OF SPLIT SKIN GRAFTING IN THE RAT
The technique used in these studies is similar to
that described by Woodruff and Simpson (1955)•
Preparation of the Recipient
Open ether anaesthesia is employed and the animal is
laid on its side on an operating board. The hair is
shaved from the side of the thorax and the skin is
cleaned with spirit. Observing strict aseptic
precautions and with the skin placed under tension by an
assistant a square of skin measuring 2 cm. x 2 cm. is
outlined using a scalpel as described by Taylor and
Lehrfield (1953)• A corner of the square of skin is
pushed up with a sharp Gillies skin hook and is placed on
tension. The pannicuius carnosus is pushed away with a
pledget until the whole square of skin has been removed.
By this means little bleeding occurs, and the fine
vessels coursing across the panniculus are not disturbed.
Technique of obtaining split skin grafts
With donor animal anaesthetised and prepared in the
same way as the recipient, the skin at the selected site
is painted with dermatome adhesive after cleansing with
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ether. A Mclndoe pattern dermatome was employed in
these studies using a blade-drum clearance of 0o008 inch
as recommended by Woodruff and Simpson (l955)• Once
cut the graft is laid on its epithelial aspect on a
square of Sofra Tulle vaseline gauze and is smoothed out
and is cut to the desired size.
Technique of applying and securing split skin grafts
The graft is laid into the prepared skin defect in
the recipient animal and is secured by a number of fine
silk sutures. The graft is protected by the application
of a plaster of Paris bandage which is removed 7 days
later.
Evaluation of graft viability
Grafts were examined daily after removal of the
dressings on Day 7« Rejection was assessed macro-
scopically and was considered to have taken place at the
time when destruction of the epithelium appeared complete.
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5. COLLECTION AJSTD PREPARATION OF
DONOR STRAIN MATERIALS
a) Blood, plasma and serum
Donor strain animals were exsanguinated by aortic
puncture„ When unclotted blood was required 300 units
of heparin were injected first,, 8 to 10 ml. per rat
was the usual volume of blood obtained by this means.
When blood was required in small amounts as for antibody
estimation it was drawn by cardiac puncture using a ly"
23 gauge needle with the animal tinder ether anaesthesia.
Plasma was obtained from heparinised blood by centri-
fugation, and serum from clotted blood after allowing
18 to 20 hours for clot retraction to occur.
b ) Erythr ocyt e s
Preliminary efforts to separate erythrocytes from
leucocytes by repeated simple centrifugation and
discarding of the buffy coat showed that a pure
erythrocyte preparation could not be achieved by this
means. The lowest degree of contamination by leucocytes
was 125,000 cells in erythrocytes derived from 1 ml. of
whole blood. Subsequently virtually pure erythrocyte
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preparations were obtained by means of an adaptation of
Harris's modification (Harris and Ukaejiofo, 1969) of
Boyum's Xsopaque-Ficoll technique (Boyum, 1968).
Ficoll-Triosil Technique for obtained either lymphocytes
or erythrocytes:-
a) Whole blood is centrifuged and the plasma is
discarded.
b) The cell mixture is passed through nylon wool
packed in the barrel of a 2 ml. syringe to
remove granulocytes and platelets.
c) The cell containing filtrate is carefully
layered onto the surface of a tube containing
5 ml. of the mixture of Ficoll (Pharmacia)
24 parts of a 9$ solution, and Triosil 75
(Glaxo) 10 parts of a 34$ solution. This is
centrifuged at 400 g for 20 minutes.
d) The resultant tube has a pale band of pure
lymphocytes near the surface. Below this lies
a broad interface of Ficoll-Triosil mixture,
and at the bottom of the tube erythrocytes are
present (Plate 26). If the lymphocytes are
required the lymphocyte band is removed to a
clean tube, resuspended in Dulbecco's solution
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Plate 26: Separation of lymphocytes from peripheral
blood using Boyum's (1968) Isopaque-Ficoll
technique„ The erythrocytes at the
bottom of the tube are separated from the
discrete band of lymphocytes by a broad
interface of Ficoll-Triosil mixture.
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and is centrifuged at 600 g for 5 minutes, and
the supernatant is discarded „ The lymphocytes
are then resuspended. Using the technique to
obtain pure erythrocytes the degree of
contamination by leucocytes was less than 500
cells in erythrocytes derived from 1 ml« of
whole blood.
c) Spleen cells
These cells are satisfactorily separated by the above
technique. The spleen is removed, cut into fragments
and homogenised. The homogenate is suspended in
Dulbecco's solution and is passed through a gauze filter
to remove large fragments. The homogenate is layered
onto the Ficoll-Triosil mixture.
d) Thoracic duct lymphocytes
Thoracic duct cannulations were carried out by
I.P, Anderson, Department of Surgery, University of
Edinburgh Medical School, according to the technique of
Bollman, Cain and Grindlay (1948).
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Special Instruments
a) Nylon cannula 0.75 mm. internal diameter (Portland
Plastics No. 1 Flex).*
b) Unmounted 17 gauge needle through which the cannula
can be threaded.
c) Metal cannula moulder** comprising a curved groove
and cover which serves to place a permanent curve
on the cannula during boiling.
d) Ligature introducer (Anderson, 1961).
e) Cannula forceps.
f) Hook. Modified from a Gillies skin hook.
g) Glass dissecting rods bent near the tip in a bunsen
flame.
Portland Plastics Limited, Hythe, Kent, England.
Designed and made by N„F. Anderson.
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Preparation of the rat
The animal is anaesthetised with open ether using a
nose-cone and is fastened in the supine position to an
operating board by means of rubber leg bands. The left
subcostal region is presented by drawing the left upper
limb over towards the right side of the chest, and the
flank is shaved.
Technique
A h cm. left subcostal incision is made which
divides skin and muscle and enters the abdominal cavity.
The intestines and the left kidney which requires to be
mobilised are packed medially with a swab, and the upper
aspect of the incision is retracted. Dissection is
carried medially to expose the aorta with the thoracic
duct lying on its lateral aspect. Two ligatures are
passed round the duct using an Anderson introducer
(Anderson, 1961). The cannula is threaded through a
17 gauge needle which is passed through the abdominal
wall below the incision.
A bevel is cut near the of the cannula which is
primed with heparin. The sharpened Gillies hook is
used to pierce the duct between the ligatures and also
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serves to elevate the near-side of the duct at the point
of entry, facilitating introduction of the cannula.
The ligatures are then tied round the cannula to retain
it in position. The wound is closed with silk in
2 layers„
Collection of lymph
When the rat approaches consciousness it is placed
in a restraining cage originally designed by Bollman
(1948) and modified by N0F0 Anderson. The rat is given
10% glucose-saline to drink, and receives a normal
laboratory rat diet. Blockage of the cannula can be
cleared by the passage of a wire stilette. The lymph
is collected in a flask which stands among ice chips.
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6. ANTIBODY DETECTION
In some experiments an assessment of alloantibody
response to donor strain antigen was required. For
this purpose a microcytotoxicity test was carried out as
described by Gelasthorpe and Doughty (1971)• A mixture
of 50% guinea pig and 50% rat complement was used. The
same guinea pig complement pool was used throughout.
Rat complement was taken from the animal supplying the
lymphocytes. There was found to be no change in titre
with this combination over guinea pig complement alone.
However the mixture reduced the natural toxicity of
guinea pig serum for rat cells to a negligible level,
thus making interpretation easier.
a) Microcytotoxicity test
The sera to be tested are diluted serially in 1 ml.
of Dulbecco's solution and 2 |1L. of each dilution is
transferred to the test plate under liquid paraffin.
Peripheral blood lymphocytes are used as target cells and
are harvested by Harris's modification (Harris and
Ukaejiofo, 1969) of Boyum's Isopaque-Ficoll technique
(Boyum, 1968). Two thousand cells in 1 |ul. of Dulbecco's
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solution are added to each, well on the plate . After
30 min. , incubation at 37°C, 1 [xl. of complement (50%
guinea pig, 50% rat) is added and a final 30 min.
incubation is begun. The wells are aspirated with a
fine glass capillary tube before staining for 10 min.
with 1 \il. of 0.5% Trypan Blue. 1 pi. 1% bovine serum
albumin in Dulbecco's solution is then added followed
by 1 [xl. 5% acetic acid as a fixative. The last
dilution having 50% or greater cytotoxicity is considered
the end point.
b) Serum fractionation
In this technique aliquots (0.5 ml.) of serum are
fractionated at room temperature (20°c) on a chromato¬
graphic column (dimensions 30 x 2.5 cm.), containing
Sephadex G200 (particle size 40-120) equilibrated in
phosphate buffered saline (pH 7-2, 0.06 M containing
0.15 M sodium chloride and 0.003 M sodium azide).
Upward flow elution with the buffer is maintained by
peristaltic pump at 5«5 ml/hr. and the column effluent
is monitored at 254 m[x. in a Uvicord 1 absorptiometer.
The fractions (volume = 1 ml.) are pooled into the
classical 19S, 7S and 4.5S fractions and a 10S fraction
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which was located in the trough between the 19S and 7S
peaks. The pools obtained are concentrated to twice
the original serum volume by ultrafiltration at 4°C
through 8/32 dialysis tubing. Prior to cytotoxicity
testing the samples are repeatedly dialysed (3 times)
at 4°C against a large volume (250 times) of phosphate
buffered saline to remove the sodium azide preservative.
7. ADMINISTRATION OF CELLS AND PLASMA
OR SERUM TO RECIPIENTS
Cells were administered suspended in Dulbecco's
solution. When intravenous administration was required
it was carried out under direct vision into the femoral
vein via a small skin incision. This method was used in
preference to percutaneous injection in order to ensure
complete intravenous administration.
CHAPTER III
Techniques associated with heterotopic
heart transplantation
-42-
1. EVALUATION OF THE TECHNICAL RESULTS OF
HETEROTOPIC HEART TRANSPLANTATION IN THE RAT
a) Operative mortality (Table l)
Of 200 rats subjected to transplantation the number
of deaths during, and for 30 minutes following operation
was 19 (9°5$). Rats receiving retransplanted hearts are
not included in this series as retransplantation is
attended by a high rate of technical failure„ Some of
the deaths attributed to anaesthesia occurred in animals
with pulmonary infections, and it was found that such
infection lowered tolerance to anaesthesia. On two
occasions some nembutal was probably inadvertently
injected intravascularly producing sudden anaesthetic
death. In 10 instances haemorrhage from the suture
line contributed to death, and in each case this was
due to faulty technique.




TABLE 1: Causes of operative deaths
among 200 rats receiving
heart transplants.
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b) Post-operative mortality (Table 2)
There were 25 animals in this group (l2.5$> of all
transplants),, Rats dying from 30 minutes after the end
of transplantation are included. The death of some
rats which occurred over 2 weeks post-operatively may
not be attributable to the procedure at all, but as no
cause for their deaths was found they are included in
the group. Among animals sacrificed were recipients
of poorly functioning heart transplants.
CAUSE OF DEATH NO „ OF RATS DAYS AFTER OPERATION
Sacrificed 4 1,1,1,6
Wound infection 2 3,12
Unknown cause 19 4,5,6,7,8,9,11,12,
14,15,24,25,60,88
TABLE 2: Post-operative causes of death among 200 rats
receiving heart transplants.
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2. INTRAPERITONEAL NEMBUTAL ANAESTHESIA.
AN EVALUATION OF THE SITE OF DEPOSITION OF
INJECTIONS USING COLLOIDAL CARBON
This brief study was undertaken in view of occasion¬
al variable results of intraperitoneal injections of
nembutalo In some instances rats appeared to be little
affected by adequate doses of the drug, and on other rare
occasions anaesthesia developed within a few seconds of
injection„
Experimental Plan
Animals. 100 F^ hybrid rats weighing 100-200 G
which were to be sacrificed in the course of a separate
experiment were used.
Technique of injection. Injections were carried
out through a 25 gauge needle with the anaesthetised
animal held supine. The abdominal wall was not "tented"
with the fingers of the other hand, and the needles were
inserted with a jabbing motion midway between xiphi-
sternum and pubis. 0.1 ml. of colloidal carbon was
injected into each rat, and laparotomy was carried out
on the dead animal within 5 minutes.
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Results
It can be seen from Table 3 that only 77% of"
injections results in intraperitoneal deposition of the
colloidal carbon. In 14% injection occurred into some
part of the gastro-intestinal tract.













Throughout the study a single surgeon (the author)
performed all of the transplant operations which number
approximately 500. While time-consuming such a
situation allows an accurate assessment of the technical
results to be made. In the early stages of the project
strict standardisation of the technique was not achieved
and the duration of operation was irregular, often being
in excess of one hour. With subsequent experience a
constant operation time of 30 minutes was achieved.
Por this reason an assessment was made of the last 200
procedures only.
More than half of the operative deaths were
potentially avoidable. Among rats dying from
haemorrhage faulty anastomotic technique was the
commonest factor. In some cases haemorrhage occurred
from coronary vessels which had been pierced inadvert¬
ently with the needle.
Some of the anaesthetic deaths were potentially
avoidable, but others to which respiratory infections
contributed could not have been anticipated.
The operative mortality may be compared with a
series reported by Tinbergen (1971) in which rat renal
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allografts were transplanted. A per-operative mortality
of 24% was recorded in a series of 282 animals. Renal
transplantation takes longer to perform than does cardiac
transplantation, and the higher mortality may in part be
related to this. However the major cause of death was
noted as "uncontrollable haemorrhage". Tinbergen did
not use the operating microscope and it seems possible
that the present study achieved technically better
anastomoses with the aid of the Zeiss binocular micro¬
scope .
Unknown factors caused the majority of post¬
operative deaths in the present study, but it is probable
that lung infections may have contributed to the deaths.
The inbred rats used are prone to such infection and rats
which have not had operations are frequently affected.
Not all of the animals dying post-operatively could be
examined post-mortem as cannibalism among the inmates of
a cage was not uncommon.
Among rats sacrificed were recipients of poorly
functioning grafts. The causes of such failures
included air embolism of the coronary vessels, and
coronary sinus occlusion due to a poorly positioned
caval ligature.
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The low incidence of wound infection can probably
be accredited largely to innate resistance of rats to
such, infection, though careful technique must have
contributed also.
The second experiment concerning the site of
deposition of intraperitoneal injections was suggested
by occasional variable results of nembutal given by this
route. Twenty-three per cent of injections did not
results in intraperitoneal deposition. This is
relatively unimportant when administering nembutal but
agents such as antilymphocytic serum might be rapidly
inactivated when injected into the stomach or small
bowel. It is possible that the use of a wide gauge
needle might result in less easy penetration of the bowel
wall o
CHAPTER IV
Demonstration of the phenomenon of prolongation
of allograft survival time following pre-treatment
of recipients with, donor strain blood
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DEMONSTRAT1ON OF THE PHENOMENON OF PROLONGATION
OF ALLOGRAFT SURVIVAL TIME FOLLOWING PRE-TREATMENT
OF RECIPIENTS WITH DONOR STRAIN BLOOD
A report by Marquet, Heystek and Tinbergen (l97l)
demonstrated prolongation of survival time of rat renal
and cardiac allografts following pre-treatment of the
recipient with donor strain blood„ The present
experiments were designed to assess whether confirmation
of this work could be obtained with regard to cardiac and
skin allografts using a different strain combination.
1. Survival time of A2/1 cardiac allografts in untreated
Hooded recipients and in recipients pre-treated
with physiological saline
Experimental design
16 Hooded rats received A2/1 cardiac allografts
without pre-treatment. A further 9 animals were pre-
treated with 2 ml. physiological saline given intra¬
venously 14 days before transplantation. In both groups
the graft survival time was assessed.
Results
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Table 4: Cardiac allograft survival in untreated
recipients, in recipients pre-treated with
sodium chloride solution and in recipients
pre-treated with donor strain blood 14 days
before transplantation.
By Student's t test the statistical
significance of the difference between the
mean of the untreated group and that pre-
treated with donor strain blood is P<0„001.
* Died of intercurrent disease with
active transplant.
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untreated Hooded recipients was 14 _+ SE 1.3 days. The
earliest rejection took place on Day 8 and the latest on
Day 31 after transplantation. A similar survival time
occurred in the group pre-treated with saline
(14 _+ SE 1.4 days), and in this group all grafts were
rejected between ^ and 20 days.
2. Survival time of A2/1 cardiac allografts in Hooded
recipients pre-treated with donor strain blood
Experimental design
15 prospective Hooded recipient rats each received
2 ml. of A2/1 blood intravenously 14 days before
receiving an A2/1 cardiac allograft. The blood was
given within 10 minutes of exsanguination of the donor
animal under direct vision into the femoral veins of the
recipients. The blood donors were injected with 300
units of heparin prior to exsanguination.
Results
Table 4 shows that the mean graft survival time in
rats pre-treated with donor strain blood was 57 _+ SE 11.6
days. This represents a 4-fold increase in survival
time as compared with untreated recipients. It is
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evident that the blood pre-treatment did not produce a
uniform increase in graft survival time in all recipient
as there was a wide range of individual variation. The
earliest rejection took place on Day 32 and the latest
on Day 108 after transplantation. In no instance did
indefinite graft survival occur.
3. Survival time of A2/1 skin grafts on Hooded
recipients pre-treated with donor strain blood
Experimental design
The protocol of administration of donor strain blood
was the same as that in the preceeding experiment„ On
Day 0 split-thickness skin grafts were applied as
described in the section on Materials and Methods.
The grafts were examined from Day +7 after application,
and the time at which rejection took place was assessed.
This was compared with a series reported by Anderson,
James and Woodruff (1967) in this laboratory using the
same strain combination.
Results
The mean skin allograft
treated group was 11 days as
survival time in the pre-
compared with a control
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time of 8 days (Table 5)- Th.e range of times of
rejection was small and all grafts were rejected within
a 3 day period„ It is evident therefore that pre-
treatment of recipients with donor strain blood has
considerably less protective effect on skin allografts


























Table 5Skin allograft survival showing the effect
of intravenous pre-treatment of recipients




Prolongation of survival time of rat cardiac allo¬
grafts following pre-treatment of recipients with donor
strain blood has been reported previously by others
(Marquet, Heystek and Tinbergen, 1971; Jenkins and
Woodruff, 197l). Marquet and his associates also
demonstrated similar protection of renal allografts and
Marino and Benain (1958) reported prolongation of
survival of skin grafts following pre-treatment of the
recipient with donor strain blood.
Pre-treatment of recipients with donor strain spleen
cells and bone marrow cells has been shown by Stuart,
Saitoh and Fitch (1968) and by Ockner, Guttman and
Lindquist (1970a) to induce prolonged survival of renal
allografts in rats.
Prolongation of graft survival time by similar
means has also been demonstrated in species other than
the rat. Protection of skin allografts in mice has been
reported by Shapiro, Martinez and Good (1961),
Billingham , Brent and Medawar (1956) and Guttman and
Aust (1961), and in rabbits by Billingham and Sparrow
(1955)> Stark, Brownlee and Grunwald (1958) and Stark
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and Dwyer (1959)-
Protection of canine renal allografts following
pre-treatment of recipients with donor spleen cells has
been reported (Halasz, Orloff and Hirose, 1964;
Zimmerman, Busch, Stuart and Wilson, 1965 ; Linn, 1966).
Others using pre-treatment schedules of lymphoid cells
or blood have not shown alteration of survival time of
such grafts (Calne, Davis, Medawar and Wheeler, 1966).
Wilson Rippin, Dagher, Kinneart and Busch (1969) were
unable to prolong survival time of such grafts using
pre-treatment with donor antigen alone but the addition
of minimal amounts of immunosuppressives after
transplantation was found to be effective.
Pre-treatment of human skin graft recipients with
donor blood has been shown by Peer, Bernhard, Walker,
Bagli and Christiensen (1957) to induce some prolongation
of time of graft survival.
Experiment 1 in the present study shows that the
mean survival time of cardiac allografts in the strain
combination used was 14 days. There was some
individual variation as compared with the survival of
skin grafts in the same strain combination as reported
by Anderson, James and Woodruff (1967)• Pre-treatment
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of recipients with. 2 ml. physiological saline 14 days
before transplantation did not affect graft survival
time .
Experiment 2 shows that pre-treatment of recipients
with 2 ml. donor strain blood 14 days pre-operatively
produced marked prolongation of cardiac allograft
survival time. The individual variation of survival
time in untreated rats was accentuated following blood
pre-treatment, and if rats which died of intercurrent
disease are excluded, the survival times ranged from
32 to 184 dayso It appears that all animals responded
to some degree and there was a moderately even scatter
of times of graft survival. It therefore seems unlikely
that more than one population of rats exists within the
group. Indefinite survival of cardiac allografts
observed by Marquet, Heystek and Tinbergen (1971)
following similar pre-treatment of recipients did not
occur in the present experiment.
Experiment 3 shows that only modest prolongation of
skin graft survival was produced by blood pre-treatment
as compared with cardiac grafts. Modification of
rejection of skin allografts is recognised to be more
difficult than that of organ allografts, and Marquet,
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Heystek and Tinbergen (l97l) did not alter skin graft
survival using a similar pre-treatment schedule to the
present experiments, Heslop (1966) however reported
some prolongation of survival of rat skin allografts
following pre-treatment of the recipients with non-viable
donor strain antigen. Viable cells were found to induce
accelerated rejection.
The mechanism by which graft survival time is
prolonged in these experiments has not been elucidated,
but immunological enhancement is a possibility. The
experiments in Chapter V are aimed at proving the
immunological basis of the phenomenon.
CHAPTER V
Demonstration of the immunological specificity of
prolongation of survival time of cardiac allografts
following pre-treatment of the recipient with, donor
strain blood
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DEMONSTRATION OF THE IMMUNOLOGICAL SPECIFICITY OF
PROLONGATION OF SURVIVAL TIME OF CARDIAC
ALLOGRAFTS FOLLOWING PRE-TREATMBNT OF THE
RECIPIENT WITH DONOR STRAIN BLOOD
The aim of this experiment was to evaluate the
specificity of the prolongation of graft survival time
demonstrated in Experiment 2, page 55. Initially
Sprague-Dawley rats were used as "third party" animals.
Subsequently Lewis rats were employed.
Experimental Plan
Group 1. Hooded recipients of A2/1 cardiac
allografts were pre-treated i.v„ with 2 ml.
Sprague-Dawley blood 14 days before
transplantation.
Group 2. Hooded recipients of A2/1 cardiac allo¬
grafts were pre-treated i.v. with 2 ml. Lewis blood
14 days before transplantation.
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Results
Table 6 shows the effect on graft survival time of
pre-treatment of prospective recipients of cardiac allo¬
grafts with "third party" blood of two different origins.
Pre-treatment with Sprague-Dawley blood resulted
in an intermediate but highly significant degree of
prolongation of survival time (27 _+ SE 2.6 days) as
compared with untreated controls (14 _+ SE 1.3 days;
Table 4).
The survival time of grafts in rats pre-treated with


































Table 6; Cardiac allograft survival showing the
effect of pre-treatment of recipients with
blood from rats of third party strain.
By Student's t test the statistical
significance of the difference between
group means are as follows.
Controls : 1 P<0.001
Controls : 2 N„S.
* From Table 4.
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DISCUSSXON
The failure of pre-treatment with Lewis blood to
affect the survival time of A2/l allografts suggests
that the phenomenon demonstrated in the previous
experiments is immunologically specific. The Lewis
strain carries the AgB^ antigen and the A2/1 the AgB^
antigen. The reason for the intermediate degree of
increased survival time produced by Sprague-Dawley blood
pre-treatment is in doubt but the most likely explanation
is the sharing of some histocompatibility antigens
between these animals and A2/1 strain rats.
Demonstration of the specificity of prolongation
of graft survival time shown in previous experiments
furthers the suggestion that enhancement is responsible
for the effect. Later experiments are aimed at
identification of antibodies in donor cell treated
recipient strain rats, and assessment of immunocompetence
of thoracic duct lymphocytes of recipient rats following
such treatment.
CHAPTER VI
Identification of the factor in donor strain blood
responsible for producing prolongation of cardiac
allograft survival time in recipient strain animals
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IDENTIFICATION OF THE FACTOR IN DONOR STRAIN
BLOOD RESPONSIBLE FOR PRODUCING PROLONGATION OF
CARDIAC ALLOGRAFT SURVIVAL TIME IN RECIPIENT
STRAIN ANIMALS
The aim of this experiment was to assess the effect
on cardiac allograft survival of pre-treatment of
recipients with donor strain plasma, erythrocytes and
leucocytes given separately in approximately those amounts
present in 2 ml. of whole blood. Initial studies
showed that this volume of blood contained on average
1.3 ml. plasma and 0.7 ml. of packed erythrocytes. The
average peripheral blood white cell count in 12 A2/1
strain male rats was 9.192 WBC/cu.mm. 88% of these
were lymphocytes. Thus 2 ml. of whole blood would be
expected to contain 18 x 10^ lymphocytes. Thoracic duct
lymphocytes were used in preference to peripheral blood
cells owing to the ease with which the cells are
harvested.
As previously mentioned the initial technique of
simple centrifugation for isolation of erythrocytes
resulted in significant contamination with leucocytes
(1.7 x 10^ leucocytes per batch of erythrocytes), and a
virtually pure erythrocyte preparation was subsequently
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obtained by Harris's modification (Harris and Ukaejiofo,
1969) of Boyum's Is opaque-Ficoil Technique (Boyum, 1968).
Two subgroups are therefore present in Group 2; 2a
received "contaminated" erythrocytes, and 2b received
virtually pure erythrocytes.
Experimental Plan
3 groups of recipient strain rats were set up.
Group 1: Pre-treated i.v. on Day -14 before
transplantation with 1,3 ml. A2/1 strain plasma.
Group 2a; Pre-treated i.v. on Day -14 before
transplantation with 0.7 ml, A2/1 strain packed
erythrocytes (plus "contamination" with 1.7 x 10
leucocytes).
Group 2b: Pre-treated i.v. on Day -14 before
transplantation with 0.7 ml. A2/1 strain packed
erythrocytes (virtually no leucocytes).
Group 3• Pre-treated i.v. on Day -14 before
transplantation with 16 x 10^ - 26 x 10^ A2/1
strain thoracic duct lymphocytes.




Table 7 shows that the mean graft survival time in
recipients pre-treated with donor strain plasma and with
pure erythrocytes was 16 _+ SE 2.1 days and 17 _+ SE 2.0
days respectively. There is no statistically
significant difference between these group means and
that of rats receiving no pre-treatment (Table 4).
This shows that neither donor strain plasma nor
erythrocytes are capable of inducing prolongation of
graft survival.
Group 3 rats which received donor strain thoracic
duct lymphocytes had a mean graft survival time of
47 _+ SE 8.0 days. The difference between this group
mean and that of rats pre-treated with donor strain
blood (57 _+ SE 11.6 days; Table 4) is not statistically
significant„
Group 2a rats which were pre-treated with 1.7 x 10^
peripheral blood leucocytes in addition to erythrocytes
showed an intermediate degree of prolongation of graft
survival (35 _+ SE 4.9 days). As with blood and with
thoracic duct lymphocyte pre-treatment there was


























































Table 7 '• Cardiac allograft survival. Effect of
pre-treatment of recipients with, donor
strain plasma, erythrocytes, and thoracic
duct lymphocytes.
By Student1s t test the statistical
significance of the differences between
the group means were as follows
Controls : 1 : 2b N„S»
Controls : 3 P<0.001
Controls : 2a P<0„001
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DISCUSS1ON
These results show the ability of donor strain
thoracic duct cells to initiate increased times of
survival of cardiac allografts when given intravenously
14 days before transplantation. The prolongation of
survival is comparable to that produced by whole blood
pre-treatment in Experiment 2, page 55. (Mean survival
time = 57 _+ SE 11.6 days). By Studentls t Test the
difference is not significant. Group 3 rats also show
considerable variation in responsiveness to the thoracic
duct lymphocyte pre-treatment as occurred with whole
blood pre-treatment. These findings suggest that the
ability of whole blood to affect graft survival time may
depend upon its lymphocyte content.
Stark and Dwyer (1959) however found that the
erythrocyte content of donor blood was responsible for
initiating prolongation of survival of rabbit skin
grafts. Moreover they found that blood leucocytes
were without effect. This is contrary to the findings
of the present experiment and it is possible that in the
rabbit histocompatibility antigens are represented on
erythrocytes. The species difference may also be a
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critical factor.
The intermediate degree of prolongation of survival
time of grafts in rats which received erythrocytes
together with leucocytes (Group 2a) suggests that the
accompanying leucocytes are responsible for the
phenomenon, and that quite small numbers of donor strain
cells are effective though to a lesser degree than the
larger number of cells used in Group 3. By inference
therefore an optimum number of such cells exists which
would produce maximum increase in graft survival time.
An assessment of this probability is included among
experiments in Chapter VII„
CHAPTER VII
Assessment of optimum conditions for pre-treatment
of recipients of cardiac allograft using donor
strain spleen cells
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ASSESSMENT OF OPTIMUM CONDITIONS FOR PRB-TREATMENT
OF RECIPIENTS OF CARDIAC ALLOGRAFTS USING DONOR
STRAIN SPLEEN CELLS
The aim of the following experiments was to assess
the optimum number of donor strain cells, the optimum
route of administration, and the optimum time before
transplantation. Spleen cells were used instead of
thoracic duct lymphocytes as their preparation was
found to be simpler and less time-consuming than
thoracic duct cannulation.
1. Assessment of optimum number of donor strain spleen
cells which induce maximum increase in cardiac
allograft survival
Experimental Plan
6 groups of recipient strain animals were set up.
2 3 4 6 7
These were injected i.v. with 10 , 10 , 10 , 10 , 10 ,
g
10 donor strain spleen cells 14 days before




Table 8 shows that pre-treatment of recipients with
10^ or more donor strain spleen cells 14 days before
transplantation induced marked prolongation of graft
7
survival time. The maximum effect occurred with 10
cells (60 _+ SE 12 »3 days). This represents a four-fold
increase over graft survival time in untreated recipients
(14 _+ SE 1.3 days; Table 4). Less marked prolongation
of survival occurred in the group which received 10^ cells
(24 _+ SE 3.9 days). Pre-treatment with 10^ or fewer
cells had no significant effect on survival of the grafts.
2. Assessment of the optimum route of injection of donor
strain spleen cells on cardiac allograft survival
Experimental Plan
7
2 groups of recipient animals were set up. 10
donor strain spleen cells were given 14 days before
transplantation intraperitoneally and intradermally„
The effect on cardiac allograft survival was assessed and
was compared with the effect of the intravenously
injected cells in the preceeding experiment.
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No. of donor strain
spleen cells injected





Individual Values Mean + SE
C\i
oH 5 13,10,14,14,14 H
1+ O 00
103 5 10,12,7,12*,31 14+4.2
-3*
oH 6 14,24,24,12,12,16 17 + 2.3







33,24*,116 39 + 12.0
Table 8 : Cardiac allograft survival. Effect of
pre-treatment of recipients with varying
numbers of donor strain spleen cells.
By Studentrs t test the statistical
significance of the differences between
the means of the groups receiving varying
pre-treatment were as follows:
No pre-treatment ±Q2 ±Q3 ±Qk
(Table k)
No pre-treatment : 108 P<0„005
No pre-treatment : 107 P <0.001
O
No pre-treatment : 10 P<0„01
106 : 107 P <0„05
107 : 108 N.S.
* Died of intercurrent disease.
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Results
These are summarised in Table 9.
The graft survival time in rats receiving intra¬
peritoneal cells was 51 days, and in rats receiving
cells intradermally it was 21 days. This is in
comparison to the effect of intravenous administration
in the previous experiment (60 days).
3. Assessment of optimum timing of treatment with donor
strain spleen cells on cardiac allograft survival
Experimental Plan
7
5 groups of recipient animals were set up. 10
donor strain spleen cells were given i.v. on Days -150,
-7, -1, 0, and +1 relative to the day of transplantation.
The effect on graft survival was assessed and was
compared with the effect of injection -14 days before
transplantation (Experiment 1, page 65).
Results
Table 10 shows that of the time schedules used cells
given 14 days before transplantation induced the greatest











Intraperitoneal 9 48,25,39,25,66,90,66,52,52 51 + 6.9
Intradermal 9 8,26,11,26,23,40,12,17,24
21 + 3-3
Table_9: Cardiac allograft survival. Effect of
variations in route of injection of 10?
donor strain spleen cells given 14 days
before transplantation.
By Student's t test the statistical
significance of the means of the groups
receiving pre-treatment by varying routes
were as follows:
Intravenous : Intraperitoneal N.S,
Intravenous : Intradermal P<0.01
Intraperitoneal : Intradermal P <0.002









Individual Values Mean + SE
-150 4 9,36,15,11 18 + 6.2
-14* 10 22,54,21,21,59,41,143,90,90,59
60 + 12.3
-7 8 25,44,55***,25,25,43,28,55*** 37 + 4.7
-1 12 12,28,24,14,27,17,
29,76,76,69,50,61*** 40 + 7.1
0** 10 13,16,42,25,32,31,42,
49,57,53 35 + 5-0
+1 5 7,12,16,16,19 14 + 2.1
Table 10; Cardiac allograft survival. Effect of
variations in timing of intravenous
injection of the recipient with 10?
donor strain spleen cells.
By Student's t test the differences
between the mean of rats receiving no
pre-treatment (N.P.T.) (Table 4) and of
rats receiving spleen cells at varying







* From Table 8.
** Heart not yet rejected,
cells on day -150 NS
cells on day -14 P <0.001
cells on day -7 P <0.001
cells on day -1 P <0.001
cells on day 0 P <0.001
cells on day +1 N.S .
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given during transplantation resulted in a mean survival
time of 35 _+ SE 5°0 days. Cells given on the day after
operation were without effect, and those given 150 days
beforehand induced only slight prolongation of graft
survival (18^ SE 6.2 days).
4. DISCUSSION
The results summarised in Tables 8, 9 and 10 show
7
that of the schedules used 10 donor strain spleen cells
given intravenously 14 days before transplantation
induced the maximum increase in graft survival time„
Ockner, Guttman and Lindquist (1970a) using donor strain
bone marrow cells to pre-treat recipients of renal
allografts also found that optimum results were achieved
ry g
with 10 to 10 cells. The present experiments show
that pre-treatment with less than 10^ cells does not
significantly affect graft survival. The survival time
ry
following injection of 10 spleen cells (60 _+ SE 12 „3
days) does not differ significantly from that induced by
pre-treatment with blood (57 _+ SB 11.6 days).
Table 9 shows that although pre-treatment given
14 days before transplantation is optimum, some
69-
prolongation of graft survival was achieved by cells
given just prior to release of the vascular clamps
during the transplant operation (35 _+ SE 5«0 days).
However cells given on Day +1 after transplantation
were ineffective, and those given 150 days beforehand
produced minimal effect. The effectiveness of late
administration of donor strain antigen in prolonging
graft survival has been noted by others (Zimmerman, 1971;
Kaliss, 1954).
The mechanism of prolongation of graft survival
following pre-treatment with donor strain cells may
relate to the balance of the cellular and humoral
components of the immune response (Hutchin, 1968), and
cellular immunity has been shown to preceed enhancement
following active conditioning (Chantler and Batchelor,
1964; Kaliss and Bryant, 1958; Mitchison and Dube,
1955)o Protocols of administration which favour
antibody production, including that of enhancing antibody
may result in prolongation of graft survival, while those
which induce a cellular immune response may cause
accelerated graft rejection.
The importance of timing of pre-treatment in some
systems may be related to subsidence of a cell mediated
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response and development of a humoral response by the
time that transplantation is performed,, Xn the present
experiments it is apparent that antigen given during
transplantation prolongs graft survival, suggesting that
little if any cell mediated immunity is induced by such
injection in this system.
Immunological enhancement is known to be associated
with the presence of 7S antibody, and Uhr (1964) has
shown that a large antigenic challenge is associated
with production of this class of antibody. In addition
small amounts of antigen may result in 19S antibody which
in some systems is capable of damaging allografts (Moller,
1966). There is no evidence in the present experiments
that small cell doses resulted in graft damage, but the
7
optimum dose of 10 cells may be related to 7S antibody
production with consequent enhancement.
As well as the dose, timing and route of
administration of the antigen, its physical form and
frequency of administration may dictate whether a
predominantly humoral or cellular response occurs.
Antigen given in multiple small injections is more
effective than when given in a single large injection
(Hutchin, 1968). The viability of the antigen also
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dictates to some extent the form of response (Billingham
and Silvers, 1971). In general non-viable preparations
give rise to more marked humoral responses. Heslop
(1968) found that enhancement of rabbit skin grafts
occurred following pre-treatment with non-viable donor
cells, but that accelerated rejection followed the use of
viable cells. There is no doubt however that different
systems present different requirements regarding the
pre-treatment protocol.
A point of interest arising from these experiments
is the wide variations of pre-treatment protocol which
are capable of inducing prolongation of graft survival.
In this system therefore there is no evidence that the
effect is dependent upon pre-treatment with antigen
according to precisely defined parameters. Not only
did accelerated rejection not occur but it was difficult
not to induce at least some prolongation of graft
survival except with extremes of protocol.
CHAPTER VXII
Administration of further donor strain blood and
sensitised recipient strain spleen cells to
recipients of cardiac allografts previously
conditioned with donor strain blood
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ADMIN1STRATION OF FURTHER DONOR STRAIN BLOOD AND
SENSITISED RECIPIENT STRAIN SPLEEN CELLS TO
RECIPIENTS OP CARDIAC ALLOGRAFTS PREVIOUSLY
CONDITIONED ¥ITH DONOR STRAIN BLOOD
The aim of this experiment was to assess whether
prolongation of survival time of cardiac allografts
following pre-treatment of recipients with donor strain
blood could be affected by a further injection of either
donor strain blood 14 days after transplantation or by
sensitised recipient strain spleen cells 21 days after
transplantation„
Experimental Plan
a) 11 Hooded rats each received an A2/1 cardiac allo¬
graft 14 days after an intravenous injection of donor
strain blood (2 ml.). 14 days after transplantation a
further similar injection of blood was given and the
effect on graft survival time was assessed.
b) 7 Hooded rats each received an A2/1 cardiac allograft
14 days after an i„v. injection of donor strain blood
ry
(2 ml.). 21 days after transplantation 10 sensitised
spleen cellswere given intravenously which were harvested
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from 3 Hooded rats 8 days after application of donor
strain split skin grafts (skin grafts were rejected on
Day 8 after application)„
Results
a) The mean survival time of cardiac allografts in this
group was 63 _+ SE 5*8 days (Fig. l) . At the time of
reporting 4 grafts were not rejected. This exceeds the
survival time in recipients pre-treated with blood but
without subsequent injections (Table 4).
7
b) 10 Hooded sensitised spleen cells given intra¬
venously on Day +21 after transplantation to conditioned
Hooded recipients of A2/1 cardiac allografts were
associated with a mean graft survival time of
66 _+ SE 1.23 days (Fig. 2). At the time of reporting
4 grafts were not rejected. This also exceeds the mean
survival time of grafts in recipients pre-treated with




















t 5 6 7 10 11 Rat No
x Graft not yet rejected
Fig. 1: Cardiac allograft survival in recipients
injected with. 2 ml. donor strain blood on




1 2 3 I 5 6 7 Rat No
x Graft not yet rejected
Fig. 2; Cardiac allograft survival. Recipients
pre-treated 14 days before transplantation
with 2 ml. donor strain blood, lo7
sensitised recipient strain spleen cells




In this system it is evident that a further inject¬
ion of donor strain blood 14 days after transplantation
does not shorten graft survival time. It is however
possible that in some cases the injection has induced
increased graft survival over and above that produced by
pre-treatment alone as 4 grafts have not yet been
rejected. It is conceivable therefore that repeated
injections of donor strain blood after transplantation
might result in still greater prolongation of graft
survival. It may be speculated that such injections
may induce a prolonged humoral response including
enhancing antibody, but little cellular immunity.
Experiment (b) shows that A2/1 cardiac allografts,
the survival of which is prolonged by pre-treatment of
the recipient with donor strain blood, are not rejected
7
when 10 sensitised Hooded spleen cells are injected
21 days after transplantation. There is little doubt
that the cells were sensitised as they were harvested
immediately following rejection of A2/1 skin grafts.
It is possible that accelerated graft rejection might
have occurred if a larger cell dose had been used, but
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this seems unlikely since the cells appear to be
associated with a greater prolongation of graft survival
than after pre-treatment with blood alone. If a state
of enhancement is induced by blood pre-treatment it
appears to be sufficiently strong to prevent sensitised
cells from causing graft rejection, and furthermore that
such cells may actually reinforce the prolongation of
graft survival.
These findings are in contradistinction to those
using rats made tolerant as neonates to allogeneic cells.
In such rats skin allografts can be made to reject by
injection of cells syngeneic with the host but from non-
tolerant animals (Gowans, Gesner and McGregor, 1961;
Billingham, Silvers and Wilson, 1963).
It is probable that in the present experiment the
sensitised cells serve to stimulate increased antibody
which further protects the graft. This further
indicates that enhancement is the likely mechanism of
the prolongation of graft survival.
CHAPTER IX
Antibody studies in recipient strain rats
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ANTXBODY STUDIES XN RECIPIENT STRAIN RATS
The preceeding experiments have established that
the increase in graft survival time induced by pre-
treatment of recipients with donor strain antigen is
specific, and that the optimum schedule of antigen
administration conforms to a typically enhancing
schedule. This suggests that the mechanism of the
effect is immunological enhancement. In order to
assess this possibility the following experiments were
carried out to attempt to demonstrate enhancing anti¬
bodies in recipient rats pre-treated with donor strain
antigen. The possibility of inducing prolongation of
graft survival time by passive transfer of serum from
conditioned recipients to otherwise untreated recipients
of cardiac allografts has also been examined.
1. Assessment of antibody titres
3 groups of recipient strain animals were set up
and antibody titres were asessed in each at weekly





7 Days after X.V.
Blood from Donor Strain
14 Days after I.V.













1 1:128 <1:8 1:64 1:32 1:32 <1:8
2 1:64 <1:8 1:16 1:8 1:8 <1:8
3 1:64 <1:8 1:64 1:8 1:8 <1:8
4 1:64 <1:8 1:32 1:16 1:8 <1:8
Table 11: Cytotoxic titres of serum fractions from
4 Hooded rats (from group a) 7 and 14 days




Group a). 11 Hooded rats were each injected intra¬
venously with 2 ml. of A2/l blood. Serum from these
rats was taken at weekly intervals and was subjected to
cytotoxicity testing. As well as this, serum from 4 of
the rats (selected at random) was subjected to G200
Sephadex gel filtration at 1 week and at 2 weeks after
injection of donor strain blood.
Group b). 7 Hooded rats each received an A2/1 cardiac
allograft as the only treatment. Serum was again taken
at weekly intervals thereafter and subjected to cyto¬
toxicity testing.
Group c). 25 Hooded rats each received 2 ml. of donor
strain blood intravenously 14 days prior to receiving
an A2/1 cardiac allograft. Serum was taken at weekly
intervals for cytotoxicity testing.
The mean _+ SD number of lymphocytes in 2 ml. of
A2/1 blood injected in Groups a) and c) was 1.22 _+ 0.17 x
7
10 cells. The viability of the cells was not less
than 98% on trypan blue exclusion.
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Resuits
Figures 3 (Group a) and 5 (Group c) show that
injection of Hooded recipients with 2 ml. of A2/l blood
i.v. induced a sudden rise in titre of antibody cyto¬
toxic to A2/1 lymphocyteso Serum samples tested one
week after injection had the highest antibody levels
detected in these groups. At 2 weeks after injection
the antibody level was considerably lower, and this was
followed by a gradual rise in both groups. The addition
of a cardiac allograft at 2 weeks in Group c) accentuated
this gradual late rise in titre. Rats which received
cardiac allografts without other treatment (Group b)
showed a steep rise in titre between 3 and 4 weeks after
grafting (pig. 4). The mean survival time of grafts
in this group was 13.4 days.
Table 11 showing results of serum fractionation
from 4 rats grom Group a) shows that at 1 week after
injection the cytotoxic activity was mainly in the 19S
fraction. At 2 weeks it was mainly in the 7S fraction,
that in the 19S fraction having subsided. No activity






Pig_o_3: Group a) rats.
Cytotoxic antibody titres in 11 Hooded rats
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Fig. 4: Group b) rats.
Cytotoxic antibody titres in 25 Hooded rats
each injected intravenously with 2 ml. A2/1
blood 14 days before receiving an A2/1
cardiac allograft. At the end of sampling
at 7 weeks one rat had rejected its graft






.rig o 5 : Group c) rats.
Cytotoxic antibody titres in 7 Hooded rats
which received cardiac allografts as the
only treatment.
The mean graft survival time was
13.4 + SE 1.4 days.
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2 o DISCUSSION
It is apparent that the pre-treatment schedule used
in these experiments results in demonstrable cytotoxic
antibodies and that such antibodies coincide with
prolongation of cardiac allograft survival time.
Correlation between antibody titre and graft survival
in Group c) is not possible since only one graft was
rejected by the end of sampling 5 weeks after
transplantation. This experiment therefore while
demonstrating an antibody response to injected allo¬
geneic cells has not confirmed that this is responsible
for prolongation of graft survival time. There is no
evidence that accelerated graft rejection takes place
in the presence of the antibody. The failure to
causally relate an antibody response to prolongation of
survival of allografts is common to other reports
(Holl-Allen, 1971; Rapaport, Dausset, Lawrence and
Converse, 1968).
Lucas, Markley and Travis (1970) however showed
dissociation of rat renal allograft survival and titre
of cytotoxic and haemagglutinating antibodies produced
in response to antigen treatment, though antibody
detectable by binding-inhibition assays was present
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in all sera capable of passively transferring enhancement.
Conversely Mayer, Kronman and Dumont (1965) found a
direct relationship between cytotoxic antibody response
to intravenously injected allogeneic thoracic duct
lymphocytes and skin graft survival in rats.
Though there is wide disagreement about the role of
cytotoxic antibodies in immune suppression they do
without doubt cause destruction of grafts in some systems.
Amos and Wakefield (1958) and Algire (1959) showed that
various tumours enclosed in cell impermeable chambers
were destroyed in sensitized hosts. Gorer and O'Gorman
(1956) found that normal as well as tumour cells are
damaged by antibody and complement. Porter (1963)
reported that in man rapid rejection of renal allografts
occurs when a major ABO-incompatibility exists between
donor and recipient. This is presumably due to the
presence of ABO antibodies in the recipient. Others
have since shown that in the presence of pre-formed
antibodies against donor cells, renal allografts are
rejected in a hyperacute fashion (Kissmeyer-Nielsen,
Olsen, Petersen and Pjeldborg, 1966; Williams, Hume,
Hudson, Morris, Kano and Milgrom, 1967; Terasaki,
Thrasher and Hauber, 1968; Russell, 1971)°
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Work by Stetson and Jensen (i960) suggests that
in established homografts there may be a blood-graft
barrier which protects grafts from access by potentially
damaging antibody. Breakdown of the barrier as might
occur during the homograft reaction might facilitate
action by the antibody„ Amos (1955) showed that
established grafts do not take up antibody, though graft
cells present within the recipients1 circulation do so.
Benacerraf, Biozzi and Halpern (195^) showed that
circulating antibody localises at the site of injections
of histamine in the skin, and Stetson and Jensen (i960)
demonstrated necrosis of skin allografts in the presence
of circulating cytotoxic antibody following injection of
histamine into the graft. The altered vascular
permeability induced by the histamine was considered to
have effectively broken the blood-graft barrier.
Table 11 shows the high antibody titre which
occurred one week after injection of antigen, and the
cytotoxic activity at that time is shown to be
predominantly in the 19S fraction. It is of some
interest that cardiac allografts transplanted at that
time (Table 10, page 67 ) still have marked prolongation
of survival time. 19S antibodies are known to be more
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cytotoxic than 7S antibodies (Moller, 1966; Takasugi
and Hildemann, 1968) and might be expected to adversely
affect graft survival. It is possible that in this
model also the grafts are protected by a blood-graft
barrier.
Group b) animals which received cardiac transplants
as the only treatment showed a sharp rise of antibody
titre between 3 and h weeks after transplantation. The
mean survival time of these grafts was 13.4 days and no
graft survived longer than 15 days. The cause of the
sudden rise in titres is uncertain but it may be due to
access of products of graft rejection to the hosts1
immune centres. Lance and Medawar (1969) noted a rise
in antibody titre following rejection of skin grafts in
mice with fading tolerance to the graft.
In conclusion it is apparent that the pre-treatment
schedule used in these studies gives rise to 7S anti¬
bodies which are known to be associated with enhancement
(Finkelstein and Uhr, 1964; Moller and Tfigzell, 1965)
2 weeks after injection of the antigen. The presence of
such antibody coincides with marked prolongation of
survival time of cardiac allografts. This provides
strongly suggestive evidence that the immunosuppression
is due to immunological enhancement.
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3 o Passive transfer of serum from recipient strain
animals conditioned with, donor strain blood
Experiment a) was designed to assess the ability of
serum raised in recipient strain animals by injection of
donor strain blood to produce passive enhancement in
otherwise untreated recipients of cardiac allografts.
The second experiment (b) was designed to assess the
effect of perfusing isolated allografts with similar
serum prior to their transplantation.
a) Injection into recipients of cardiac allografts
Experimental Plan
12 Hooded recipients of cardiac allografts were
injected with serum from recipient strain rats which had
previously been conditioned with A2/1 blood given intra¬
venously. 3 different protocols of serum administration
were used. The serum for recipients 1-5 was from rats
conditioned with a single injection of blood 14 days
before exsanguination. Recipients 6-15 received serum
raised by conditioning injections 14 days and 7 days
before exsanguination. The cytotoxic titres of these
sera were assayed. Serum was injected intravenously
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except for some injections to rats 13-15 which were
given intraperitoneally. The schedule of administration
is shown in Table 12 .
The cardiac allograft survival time was assessed
in all groups.
Results
Table 12 shows that injection of heart recipients
with serum from Hooded donors previously conditioned
with A2/1 blood did not affect graft survival time.
b) Perfusion of serum through isolated cardiac
allografts prior to transplantation
Experimental Plan
Serum donors of recipient strain were conditioned
with 2 ml. donor strain blood given intravenously 14 days
prior to exsanguination. The cytotoxic titre of this
serum was not assayed.
Immediately following removal of each heart a fine
portex cannula was introduced into the aorta and was
secured with a ligature. 2 ml. of serum was perfused
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circulation. Following removal of the ligature and
cannula a cuff of aorta was excised and transplantation
was carried out,,
Results
It can be seen from Table 12 that perfusion of
hearts prior to transplantation with serum from Hooded
donors previously conditioned with A2/1 blood did not
affect graft survival time (16 _+ SE 1.1 days) „
ko DISCUSSION
Part (a) of this experiment shows that serum from
recipient strain rats conditioned with donor strain
blood does not prolong graft survival time when
passively transferred to allograft recipients in spite
of using serum with a cytotoxic titre as high as 512
(recipients 6-12). It is possible that the antibody
doses or the schedules of administration were not optimum.
Haughton and Nash (1969) however showed that enhancement
of mouse tumours could be achieved by injection of
sub-microlitre doses of passively transferred antibody.
Other studies suggest that large doses of serum must be
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given in passive transfer experiments with, normal
tissues (Brent and Medawar, 1961; Heslop, 1966; Nelson,
1961; Nelson, 1962) since the half-life of Y globulin
is quite short (Hutchin, 1968; Dixon, Talmage, Maurer
and Deichmiller, 1952). It is also likely as suggested
by Hutchin (1968) that a prerequisite of an enhancing
serum is that it should contain antibodies against all
antigenic receptors of the allogeneic graft donor.
This has probably been achieved in some studies by
hyperimmunisation of the serum donor. Stuart, Saitoh
and Fitch (1968) and Lucas, Markley and Travis (1970)
8
used three injections of 10 donor strain spleen cells
the first accompanied by Freund's adjuvant to raise an
allo-antiserum for passive enhancement of rat renal
allografts. Studies by Stimpfling and Pizarro (1961)
suggest that in mice it is necessary to hyperimmunise
to induce antibodies against the weaker antigens.
Most reports of passive enhancement of organ
allografts concern rat renal transplants. Stuart,
Saitoh, Fitch and Spargo (1968) demonstrated passive
enhancement of such grafts using allo-antiserum.
French and Batchelor (1969) showed passive enhancement
of rat renal allografts which was most striking when F^
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hybrid kidneys were used, and less so with allogeneic
homozygous kidneys. They found that 3.5 ml, of serum
with a cytotoxic titre of 1/256 given in divided doses
was effective. More recently Ockner, Guttman and
Lindquist (1970b) demonstrated reduced intensity of
rejection of rat renal allografts after injection of
recipients with a globulin fraction of serum from
recipient strain animals pre-treated with donor strain
bone marrow cells.
Prolongation of graft survival time in part (b)
of this experiment would depend on antibody acting
peripherally on the graft as suggested by Morris and
Lucas (1971) rather than on the antigen processing or
immune centres of the recipient. It is possible that a
substantial part of the enhancing process occurs
centrally, and the failure of the technique of graft
perfusion to prolong survival time could be ascribed to
this factor. Alternatively it is possible that the
duration of contact between antibody and graft was too
brief to produce an enhancing effect.
It is evident that a number of objections can be
raised to the design of the two parts of this experiment
and it is considered that the result does not exclude
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enhancement from being the mechanism of prolongation of
graft survival time demonstrated in the earlier
experiments. A further investigation required is
passive transfer of non-complement fixing Y globulin
subclasses from serum of conditioned animals into graft
recipients rather than crude serum as used in these
experiments. Given sufficient serum donors much
larger volumes of the active subtraction could be given.
CHAPTER X
Assessment of the immunocompetence of recipient
strain rats pre-treated with, donor strain blood
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ASSESSMENT OF IMMTMOCOMPETENCE OF RECIPIENT STRAIN
RATS PRE-TREATED WITH DONOR STRAIN BLOOD
The aim of these experiments was to determine
whether or not injection of Hooded rats with A2/1 blood
induces a state of tolerance in the sense used by
Billingham, Brent and Medawar (1953) in which there is a
state of specific non-reactivity to cells possessing
foreign alloantigens.
Also assessed is whether or not injection of
allogeneic blood results in temporary recruitment of
antigen reactive cells from the recirculating lymphocyte
pool.
The first experiment is an evaluation of the
graft-versus-host assay of Ford, Burr and Simonsen (1970).
In the second this assay is used to determine the immune
reactivity of thoracic duct lymphocytes of Hooded rats
at varying intervals after injection with A2/1 blood„
The reactivity of thoracic duct lymphocytes from rats
pre-treated with donor strain blood and carrying long
surviving cardiac allografts is also assessed„ The
third experiment is a test of the ability of Hooded rats
pre-treated with A2/1 blood and bearing long surviving
cardiac allografts to reject donor strain split skin
grafts.
-90-
1. Assessment of the graft-versus-host response in F^
hybrid animals to lymphoid cells from untreated
Hooded rats
Local graft-versus-host reactions have been produced
in numerous anatomical sites such as the skin (Brent and
Medawar, 1963), the kidney (Elkins, 1964) and the
peritoneal cavity (Weiser, Granger, Brown, Baker, Jutila
and Holmes, 1965). Efforts to quantitate local graft-
versus-host reactions have resulted in a variety of
techniques of differing degrees of usefulness. Ford
(1967) described a local graft-versus-host assay based on
the reaction of parental cells injected intradermally into
F^ hybrid animals. Its usefulness is evidently limited
by difficulties with quantitation, and contamination of
the inoculum with red blood cells makes it unreliable.
Elkins (1964) introduced a technique in which the
cell inoculum is injected beneath the renal capsule of
the F-^ hybrid recipient. On the 7th day a histological
grading can be made depending on the degree of activity
exhibited by the infiltrate.
Levine (1968) reported a method which evolved from
attempts to inject parental spleen cells directly into
surgically exposed lymph nodes. Leakage of the
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inoculum from the nodes occurred and quantitation was
found to be impossible„ Subsequent injections were
given intradermally into the footpad which gave marked
weight increase of the popliteal lymph node from 6 mg«
up to 185 mg. in 5-H days. This principle was employed
by Ford, Burr and Simonsen (1970) and by Haskova and
Gansova (1970)• A reproducible technique was developed
and was used in the present experiments. Lagunoff
(1969) showed by means of infusions of labelled autoch¬
thonous lymphocytes that the node enlargement is not due
to trapping of circulating cells. Ehrich, Drabkin and
Forman (1949) demonstrated hypercellularity and DNA
increase in similar nodes.
Ford and his associates found that subcutaneous
injections gave more reliable results than intradermal
and they established a dose-node weight increase
relationship. They found the method more reliable than
others and report it as 10 times more sensitive than the




5 groups of F^ hybrid rats were set up. Using the
graft-versus-host assay of Ford, Burr and Simonsen (1970)
7
each animal in Gfoups A to D received 10 lymphoid cells
in 0.1 ml. Dulbecco's solution injected subcutaneously
into the right hind footpad. Group E animals received
0.1 ml. of Dulbecco's solution alone. The animals were
killed at 1 week and the popliteal nodes from both sides
were weighed.
7
Group A; 20 F^ hybrid rats each received 10 Hooded
thoracic duct lymphocytes from 3 donors.
7
Group B: 13 F^ hybrid rats each received 10 Hooded
spleen cells pooled from 2 donors,
7
Group C: 10 F.^ hybrid rats each received 10 F^
(syngeneic) thoracic duct lymphocytes from a single donor,
7
Group D: 10 F-^ hybrid rats each received 10 F^
(syngeneic) spleen cells from a single donor.




These are summarised in Table 13 « Injection of
parental strain thoracic duct lymphocytes induced marked
increases in weights of the draining popliteal nodes as
compared with the contralateral nodes of F hybrid rats.
The combined mean of the test nodes in Group A was
55.61 mg. (51.64 - 59.88). This is approximately 10
times the mean weight of the contralateral nodes.
Injection of parental strain spleen cells induced
less marked node weight increases. The mean weight of
nodes in this group was 35.17 mg. (33.12 - 37.34).
Injection of syngeneic thoracic duct lymphocytes
and spleen cells into F^ hybrids induced slight node
weight increases of the order of 2 mg. This effect has
been noted previously by Ford, Burr and Simonsen (1970).
Dulbecco's solution was without effect.
2. DISCUSSION
Table 13 shows that inoculation of F^ animals with
7
10 parental TDLs produces marked increase m the mean
weights of the draining popliteal nodes (geometric mean
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Table 13: Effect of injection of 10 lymphoid cells
of parental and isogeneic origin on
popliteal lymph node weights of hybrid
rats .
By Student's t test the statistical
significance of the difference between
the means of group a) combined and
group b) is P <0.001.
1, Popliteal node from injected side.
2. Geometric mean (mg). The numbers in
parentheses show the effect of add¬
ing or subtracting 1SE of the log
mean.
-94-
This represents a ten-fold weight increase over the
contralateral nodes and approximates to the findings of
£
Ford, Burr and Simonsen (1970) when 9 x 10 parental
TDLs were used.
Ford and his associates found that a saturation
effect occurred when injecting a number greater than
9 x 10^ parental cells and a larger number of cells
did not produce a significantly greater lymph node weight,
7
In the present study a dose of 10 parental cells was
selected and no attempt has been made to correlate node
weight response to cell dose.
Table 13, Group B shows that spleen cells induce
approximately a five-fold node weight increase and
therefore appear to be less active than thoracic duct
lymphocytes in inducing a graft-versus-host response.
The importance of the circulating small lymphocyte in
initiating graft-versus-host reactions has been
emphasised by Gowans, Gesner and McGregor (1961), and
the relatively poor reactivity of spleen cells is
probably a reflection of this. Using mice Cantor,
Mandel and Asofsky (1970) showed that blood and thoracic
duct lymphocytes are more than four times as active as
are spleen cells in producing graft-versus-host reactions.
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Injection of syngeneic thoracic duct lymphocytes
and spleen cells produced small but consistent increases
in node weights of about 2.0 mg. per node. This must be
a non-specific effect unrelated to the trauma of
injection since injection of Dulbecco's solution alone
had no effect on node weights.
3. Assessment of the graft-versus-host response in F^
hybrid animals to thoracic duct lymphocytes from
Hooded rats pre-treated with A2/1 blood
Recent reports of in vitro and in vivo studies have
demonstrated the selective binding or recruitment by
antigen of a specific subpopulation of antigen sensitive
cells (¥igzell and Anderson, 1969; Dutton and Mishell,
1967; Ada and Byrt, 1969; Ford and Atkins, 1971;
Sprent, Miller and Mitchell, 1971).
Ford and Atkins (1971) showed that passaging parental
strain thoracic duct lymphocytes through an irradiated
F-j hybrid rat resulted in recruitment of a subpopulation
of these cells. Thoracic duct cells from the hybrid
which were shown to be mostly of parental origin had a
reduced graft-versus-host capability against similar F^
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hybrid animals, but not against third party hybrids.
This specific unresponsiveness of passaged parental
cells which was noted in the 12-36 hour lymph collection
did not return at any time during the 5«5 day collection
period.
Sprent, Miller and Mitchell (1971) showed also that
thoracic duct lymphocytes from parental strain mice
injected intravenously 1-2 days previously with F^ hybrid
spleen cells had no demonstrable graft-versus-host
activity against similar F^ hybrid animals but had normal
activity against third party F^ hybrids. The activity
which was found to be absent up to 2 days was considerably
augmented by day 5. They also showed that thoracic duct
lymphocytes from mice 1-2 days after injection of sheep
erythrocytes did not adoptively transfer immune
reactivity to sheep erythrocytes in thymectomised,
irradiated, marrow protected syngeneic hosts, but were
normal with respect to horse erythrocytes. Cells
collected at day 3 had a normal activity and cells
collected at day 5 had augmented activity.
The ability of intravenous injections in some
systems to produce temporary deficiency of specific
antigen reactive cells in the recirculating lymphocyte
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pool suggests that the blood or spleen cell pre-treatment
schedule used in experiments in this thesis might produce
a similar effect and that it might possibly be linked to
programming of cells to produce enhancing antibody.
The aims of this experiment therefore were:-
a) To assess whether or not the recirculating
pools of lymphocytes of Hooded rats become
temporarily deficient in cells specifically
reactive to the antigen in A2/1 blood after an
intravenous injection of such blood.
b) To determine whether pre-treatment with donor
strain blood alters the graft-versus-host
reactivity of thoracic duct lymphocytes of
such rats 14 days after injection (i.e. at the
optimum time for heart transplantation).
c) To assess the graft-versus-host reactivity of
thoracic duct lymphocytes of rats which have
been pre-treated with donor strain blood and




Hooded thoracic duct lymphocytes were harvested at
varying intervals after intravenous injection of the
donors with 2 ml. A2/1 blood. The first collection
began at the time of injection of the blood, and the
last was on day 14 after injection. Two or more donors
contributed to each pool of thoracic duct cells.
Eight cell pools were harvested. A further pool of
cells was provided by a Hooded rat pre-treated with donor
strain blood 14 days before receiving a donor strain
cardiac allograft. The graft was still active 21 days
after transplantation when thoracic duct cannulation
was performed.
A graft-versus-host assay of each pool was carried
out in hybrid rats using the method described by
Ford, Burr and Simonsen (1970) . Each F-^ hybrid was
7
injected in one footpad and 10 cells in 0.1 ml. Dul-
becco's solution and both test and contralateral
popliteal nodes were weighed at one week.
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Results
Table 14 shows the popliteal node weight increases
in F^ hybrids following injection of thoracic duct
lymphocytes harvested from Hooded rats at varying
intervals after pre-treatment with a2/1 blood. No cell
pool induced a graft-versus-host reaction, as assessed
by increase in weight of the popliteal nodes, which was
significantly different from that produced by cells
from untreated Hooded rats (Table 13, Group a)»
Table 14 also shows that thoracic duct lymphocytes
from a pre-treated Hooded rat bearing a long surviving
A2/1 cardiac allograft also had normal graft-versus-host
reactivity in F^ hybrid rats.
Xt therefore follows that no recruitment of antigen
reactive cells was demonstrated in response to injection
of the thoracic duct cell donors with allogeneic blood.
It is evident that the injection of blood, shown in
previous experiments to prolong cardiac allograft
survival, does not induce a state of immunological
tolerance. Pre-treated rats carrying long surviving
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Table 14: Effect of injection of 10 Hooded thoracic
duct lymphocytes (harvested at varying
intervals after intravenous injection with
A2/1 blood) on popliteal lymph node weight
of Fj_ hybrid rats. Effect of cells from
a pre-treated Hooded rat carrying a long
surviving cardiac allograft.
By Student1s t test the difference between
the means of group a (Table 13) and that of
rats injected with thoracic duct lympho¬
cytes taken 0-h hours after injection of
allogeneic blood is not statistically
significant„
1. Popliteal node from injected side.
2. Geometric means (mg). The numbers in
parentheses show the effect of




Using this system there is no demonstrable
recruitment of a subpopulation of cells from the
recirculating lymphocyte pool following injection of
A2/1 blood. Furthermore there is no evidence that
thoracic duct lymphocytes from donors injected with
allogeneic blood have an increased capacity to produce
a graft-versus-host reaction at any time following
injection. Sprent, Miller and Mitchell (1971) found
that thoracic duct lymphocytes from mice injected with
F1 hybrid spleen cells five days previously had increased
graft-versus-host activity in similar F^ hybrids.
However as the present experiment did not include
sampling at that time interval increased reactivity of
the thoracic duct lymphocytes cannot be excluded. In
addition slight latent variations of the graft-versus-
host reaction cannot be excluded since no attempt was
made to quantitate the reaction using varying doses of
parental cells.
However in principle these findings are in contrast
to those of Sprent, Miller and Mitchell (1971) who used
mice and with Ford and Atkins (1971) but it is conceeded
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that a very different system has been used. Ford and
Atkins (l97l) report that unpublished work of Gowans,
Rowley, Ford, Atkins and Smith has demonstrated that in
rats after intravenous injection of "several kinds" of
antigen the recirculating lymphocyte pool does become
specifically deficient in cells capable of mediating an
immune response. Furthermore they also indicate that
they have used F-^ hybrid cells as antigen in parental
strain rats and have shown in this system some selection
of antigen reactive cells„
As distinct from specific diminution of the
graft-versus-host reaction occurring within 2 days of
injection of antigen, there is general agreement that
rats bearing enhanced renal or cardiac allografts over
prolonged periods show normal graft-versus-host
reactivity with donor strain antigen. Marquet, Heystek
and Tinbergen (1971) demonstrated normal reactivity of
lymphoid cells from enhanced rats bearing cardiac and
renal allografts between 1 and 15 weeks after
transplantation. Ockner, Guttman and Lindquist (1970b)
showed normal reactivity of cells from enhanced rats
bearing renal allografts 7 days after grafting, and
French, Batchelor and Watts (1971) demonstrated normal
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reactivity of cells from rats with enhanced renal
allografts between 2 and 5 months after transplantation.
In summary this experiment does not demonstrate
recruitment from the recirculating lymphocyte pool of
cells reactive against donor antigen at any time
following the initial conditioning injection with donor
strain blood. It does however show that the
conditioning injection does not induce a state of
tolerance to the donor strain, and also that the
prolongation of allograft survival induced by donor
strain blood pre-treatment is not due to tolerance.
5. Evaluation of the ability of Hooded rats pre-treated
with A2/1 blood and bearing long surviving cardiac
allografts to reject donor strain split skin grafts
The experimental aim was to confirm that prolonged
acceptance of cardiac allografts following injection
with donor strain blood is not due to induction of
specific tolerance.
Experimental Plan
5 recipient strain rats were each injected i.v. with
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2 ml. donor strain blood 104 days before skin grafting,
and cardiac allografts from the same donor strain were
transplanted 14 days after the blood injections. At
the time of applying split skin grafts the cardiac grafts
were active.
Results
Table 15 shows that all skin grafts were rejected
by the recipients in the time characteristic of control
grafts (8 days).
6. DISCUSSION
This experiment demonstrates that rats pre-treated
with donor strain blood and bearing long surviving
cardiac allografts are fully capable of rejecting
donor type skin grafts as quickly as untreated controls.
These findings are contrary to those of Marquet,
Heystek and Tinbergen (1971) and of French, Batchelor
and Watts (1971) who demonstrated that enhanced rats
bearing long surviving organ allografts also accept
donor type skin grafts for prolonged periods. Lucas,




























Table 15: Survival time of A2/1 split thickness
skin allografts on Hooded recipients of
long surviving A2/1 cardiac allografts.
Recipients pre-treated 14 days before
cardiac transplantation with 2 ml. donor
strain blood.
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however found that rats bearing enhanced renal allografts
rejected donor type skin as quickly as did controls.
The results of this and the preceeding experiment
unequivocally demonstrate that the pre-treatment schedule
used does not induce a state of tolerance to the donor
antigens. The problem remains then to propose a
mechanism by which the acceptance of a cardiac graft
can be reconciled with rejection of a skin graft from
the same source. The simplest explanation is that
enhancement, perhaps on a waning scale, is responsible
for cardiac graft survival but by 104 days has become
inadequate for protection of skin grafts which are
recognised to be difficult to enhance even under ideal
conditions (Hutchin, 1966). Experiment 3j page 67?
suggests that even cardiac grafts do not have prolonged
survival when inserted 150 days after the enhancing
injection and it is possible that the presence of a
cardiac allograft may produce some self-perpetuating
enhancement. Alternatively some form of graft
adaptation as discussed on page 109 may reduce anti¬
genicity of cardiac grafts which in the earlier stages
were protected by strongly developed enhancement.
CHAPTER XI
Evaluation of possible alteration of antigenicity of
long surviving cardiac allografts
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EVALUATION OF POSSIBLE ALTERATION OF ANTIGENICITY
OF LONG SURVIVING CARDIAC ALLOGRAFTS
The subject of adaptation of allografts has been
reviewed by Woodruff (i960), and it has been shown that
allografts placed in the anterior chamber of the eye
become less vulnerable to rejection with the passage of
time (Woodruff and Woodruff, 1950) . The mechanism of
adaptation has not been elucidated, but the phenomenon
may be of importance in clinical transplantation when,
as sometimes happens, recipients of renal allografts
require less immunosuppression as time passes.
1. Retransplantation of cardiac allografts
This experiment represents an attempt to assess
possible reduction of antigenicity of long surviving
allografts in "conditioned" recipients by retransplantat¬
ion into otherwise untreated recipients.
Experimental Plan
Long surviving A2/1 cardiac allografts (in excess
of 64 days) were removed from initial Hooded recipients
which had been pre-treated i„v„ with 2 ml. donor strain
blood 14 days before operation, and were retransplanted
-106-
into secondary hosts. Heart No. 1 was retransplanted
back into a donor strain (A2/l) animal. Nos. 2-6 were
retransplanted into recipient strain (Hooded) animals.
The graft survival time in the secondary hosts was
assessed.
Results
These are summarised in Table 16.
Retransplantation of heart No. 1 back into the
original donor strain (A2/l) resulted in survival of the
graft until the recipient was sacrificed at 100 days„
Marked variation in time of survival occurred in hearts
2-6 which were retransplanted to untreated recipient
strain rats. The mean survival time of these hearts
was 21.5 days. The standard error however amounted to
25$ of the mean value. Those hearts which remained
longest in conditioned recipients were rejected soonest
in secondary recipients, while those which spent the
shortest time in the conditioned recipients survived
















1 65 A2/1 100* 100
2 69 Hooded 35 ;
3 162 Hooded 10 <
4 86 Hooded 25 ; 21 + 5-1
5 162 Hooded 9 ■
6 90 Hooded 28 '
Table 16: Cardiac allograft survival. Effect of
retransplantation of long surviving A2/1
cardiac allografts from initial recipient
strain (Hooded) animals (conditioned on
day -14 before transplantation with 2 ml.




The principal defect of this experiment is the
small number of constituent animals. Retransplantation
of hearts is technically difficult and is attended by a
high mortality. However it is evident that the
antigenicity of hearts with prolonged survival in
conditioned allogeneic hosts is not qualitatively
altered, as heart No. 1 survived in the final recipient
of donor strain until termination of the experiment at
100 days. Hearts Nos. 2-6 showed wide individual
variation of survival time and the difference between
the mean survival of these hearts (21 _+ 5 = 1 days) and
that of controls in Table 4 (14 _+ 1,3 days) is not
statistically significant (P <0.25). However it is of
interest that hearts Nos. 3 and 5 in Table 16 which were
rejected soonest (10 days and 9 days) had resided the
longest in the intermediate hosts (162 days).
Conversely heart No, 2 which remained for the
shortest time in the intermediate host (65 days) had the
longest ultimate survival time.
Clearly conclusions drawn from this aspect of the
experiment must be guarded in view of the small number
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of constituent animals. However it seems possible that
some hearts retransplanted from "conditioned" inter¬
mediate hosts may have some quantitative alteration in
antigenic!ty.
Others have demonstrated a similar effect with rat
renal allografts. Ockner, Guttman and Lindquist (1970b)
using an enhancement model showed that "when several long
surviving LBN allografts were retransplanted into
normal L recipients, rejection did not occur normally".
Marquet, Heystek and Tinbergen (l97l) also noted
prolonged survival of a single rat which was the
recipient of a renal allograft which had been enhanced
for 1 year in an allogeneic intermediate recipient.
The mechanism of prolonged survival following
retransplantation is open to conjecture, but antibody
coating of antigenic sites, cellular substitution, and
loss of certain antigenic cells require consideration.
It seems inconceivable that "coating" antibody could
persist long enough to give prolonged graft survival,
though continuous endogenous production of antibody
with consequent graft protection seems possible.
Unlike skin grafts cardiac grafts could hardly be
replaced by "creeping substitution" of constituent
-109-
cells. The third possibility remains.
Recently much interest has centred round the role
of the "passenger leucocyte" within grafts, and the
subject has been reviewed by Billingham (l97l). Several
studies suggest that much of the antigenicity of a graft
is related to the content of passenger leucocytes lying
in the capillary bed and tissue spaces of the organ.
Ockner, Guttman and Lindquist (1970b) have suggested
that the mechanism of enhancing antibody in prolonging
the lives of certain types of allografts may depend on
its capacity to destroy passenger leucocytes. Several
experiments have recently been reported which emphasise
the importance of these cells. Guttman, Lindquist and
Ockner (1969) have shown that renal isografts that carry
allogeneic passenger cells develop signs of rejection
after transplantation. Conversely it was found that
abrogation of rejection of rat renal allografts could be
obtained by replacement of the prospective donor's
haemopoietic cells with cells isologous with the future
host. Guttman, Carpenter, Lindquist and Merrill (1967)
also noted that renal allografts from donors treated
with ALS are not rejected by normal rats as quickly as
kidneys from untreated donors, which suggests a partial
-110-
elimination of ALS susceptible antigenic cells from the
grafts.
Recently Freeman, Chamberlain, Reemtsma and
Steinmuller (1971) have demonstrated the importance of
passenger cells in rat cardiac allografts by treatment
of prospective donors with agents designed to produce
leucopoenia which resulted in prolongation of survival
time of the grafts.
It is probable therefore that allografts do owe
part of their antigenicity to passenger cells and that
elimination of such cells may prolong allograft survival.
It seems unlikely however that grafts could be made
non-antigenie even by total elimination of all
passengers, since presumably muscle and other cells also
carry antigen determinants. Late rejection crises of
human renal allografts occurring some years after
transplantation are well recognised, and it seems
inconceivable that persisting passenger cells of donor
origin could be the instigators of such events.
An alternative way in which cells may lose anti¬
genicity is by "antigenic modulation". Old, Stockert,
Boyse and Kim (1968) demonstrated loss of the TL antigen
by mouse thymocytes through the action of specific
-Ill-
antibody o Coating of antigen with antibody was
excluded. However no evidence has yet been produced




The experiments in this thesis have shown that
pre-treatment of recipients of cardiac allografts with
donor strain blood, thoracic duct lymphocytes, and
spleen cells induces marked immunologically specific
prolongation of graft survival time. It appears that
a further injection of donor blood after transplantation
may produce additional prolongation of graft survival.
Using spleen cells the optimum conditions for induction
of the phenomenon were demonstrated, and a four-fold
increase in survival time was achieved. It is of
interest that in no case did injection of recipients
with donor strain cells before or after transplantation
induce accelerated graft rejection.
The mechanism of the effect has not been proved
conclusively, but the optimum pre-treatment dose, timing,
and route of administration are suggestive of an
enhancing regime. Demonstration of 7S antibodies in
response to donor strain antigen furthers this suggestion
since enhancing antibodies are known to be of this class.
Although such antibodies have been shown to occur
following pre-treatment of recipients their causal
'
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relationship to prolongation of graft survival time is
more difficult to assess, and this point has not been
precisely defined in the present study„
It is of interest that passive transfer of serum
from pre-treated rats to recipients of cardiac allografts
did not prolong graft survival. At first sight this
seems to suggest that serum factors may not be responsible
for abrogation of rejection in the earlier experiments.
However it is possible that the optimum dose of serum
was not given, or that hyperimmunisation of the serum
donor may be necessary to raise an effective serum.
Others have raised effective sera using three spaced
g
injections of 10 donor strain cells, the first
accompanied by Freund's adjuvant (Stuart, Saitoh and
Pitch, 1968; Lucas, Markley and Travis, 1970). As well
as this in most studies F.^ hybrid graft donors have been
used which reduces the degree of antigenic disparity
between donor and recipient.
It is evident that the pre-treatment schedule of
prospective cardiac allograft recipients does not induce
immunological tolerance since thoracic duct lymphocytes
of such rats had normal graft-versus-host reactivity in
hybrid animals. In addition evidence of some degree
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of rejection was found in all heart transplants removed
from pre-treated animals, which suggests that such rats
recognise and react against the foreign antigen. The
ability of pre-treated rats carrying long surviving
cardiac allografts to reject donor type skin grafts
further indicates that such rats are not immunologically
tolerant.
Application of enhancement to human recipients of
allografts is an attractive prospect since the immuno¬
suppression is specific and its use would not entail the
complications produced by agents which act non-
specifically.
Before considering the use of enhancement clinically
experiments using a variety of different species are of
obvious interest. In general most rodents appear to
exhibit enhancement though until recently it was thought
that the Syrian Hamster was an exception in view of
failure to raise sera with cytotoxic or haemagglutinating
properties from these animals (Billingham and Silvers,
1964a; Palm, Silvers and Billingham, 1967). It was
deduced that the hamsters were unable to form cytotoxic
antibodies in response to skin allografts (Billingham
and Silvers, 1964b; Shaffer, 1969) . However Ramseier
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and Lindemann (1971) have produced evidence that the test
system used in these studies was inadequate. Efforts to
enhance canine renal allografts have met with varied
success. Wilson, Rippin, Dagher, Kinneart and Busch
(1969) and Holl-Allen (1971) showed that protection of
such grafts could be achieved by a combination of donor
cell pre-treatment and minimal doses of immunosuppressive
drugs.
It thus appears that at least some experimental
animals do display the phenomenon of enhancement though
to varying degrees, and it is possible that man is not an
exception. However it would be unwise to presume that
allografts in the rat and in man are affected in the same
way by preformed antibodies. The apparent impossibility
of inducing hyperacute rejection of rat cardiac allo¬
grafts suggests that this is not so, Chavez-Peon,
Monchik, Winn and Russell (l97l) have suggested that the
rat model may not be an appropriate one for clinical
studies, and have also shown that renal allografts in
rats which have high levels of circulating allo-
antibodies are not subjected to very early and acute
destruction. They also demonstrated however that the
rat is capable of mounting reactions which are
-Ir¬
responsible for hyperacute rejection by the use of
xenografts. In addition Kissmeyer-Nielsen, Olsen,
Petersen and Fjeldborg (l966) and others have pointed
out that in man the presence of preformed antibody to
donor cells in recipients of renal allografts ensures
hyperacute graft rejection.
A technique which avoids the damaging effects of
antibody on graft survival has been used by Batchelor,
French, Cameron, Ellis, Bewick and Ogg (1970) to
passively enhance a renal allograft in a child. The
patient received non-complement binding antibody
fragments derived from serum prepared by immunising the
father with leucocytes from the mother who was also the
graft donor. It was found that no further immuno¬
suppression was required for three months. A further
approach might lie in making antibody preparations non-
cytotoxic by separating out enhancing from cytotoxic
portions (Russell, 1971).
It seems reasonable to speculate that passive
enhancement will come to be used clinically as a means of
combating rejection, possibly in conjunction with
standard immunosuppressive agents. In this way it may
be possible to reduce the dose of drugs to a level at
-117-
which side effects are negligible „
Protection of allografts in man by pre-treatment of
recipients with donor cells is a less likely eventuality
in view of the reported effect of cytotoxic antibody on
human allograft survival. If however the technique
does prove ultimately to have clinical potential the
inherent advantages are obvious. The present study has
shown that donor cells exert a protective effect on rat
allografts when given as late as during transplantation
itself. If this is true in man also, it would be
possible to harvest the cells and graft simultaneously.
The method could then be used when as frequently happens
organ donors present with little prior warning.
Specific immunosuppression provides a new and
potentially rewarding approach to the problem of
rejection in clinical transplantation. It is not
suggested that it will replace conventional immuno¬
suppressive techniques in the foreseeable future, but it
is to be hoped that at least it may prove a valuable
adjunct to such treatment. At best there is the
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